1 IN THE COURT OF COMMON PLEAS 2 CIVIL DIVISION 3 SUMMIT COUNTY, OHIO 4 KAREN WILSON, Administratrix, the) Case No.: 5 6 The Estate of GERALDINE BAILES,) CV-2002-06-3340 7 Plaintiff,) 8 vs. 9 YOUN PARK, M.D., et al., 10 Defendants. - } 11 12 The video teleconference deposition of 13 BARRY WENIG, M.D., called by the Defendants for 14 examination, taken before JOANNE H. RICHTER, a 15 Notary Public within and for the County of Cook, State of Illinois, and a Certified Shorthand 16 17 Reporter of said state, No. 84-2082, at Northwestern University, University Library, 18 1970 Campus Drive, Evanston, Illinois, on the 19 19th day of August, A.D. 2003, at 9:00 a.m. 20 21 22 23 24 LINKING TESTIMONY, TRADITION AND TECHNOLOGY E S O U I R E

1

) 🛃

R

) \$

-	PRESENT:
2	FRIEDMAN, DOMIANO & SMITH CO., L.P.A.,
3	(Sixth Floor - Standard Building,
4	1370 Ontario Street,
5	Cleveland, Ohio 44113-1704,
6	216-621-0070), by:
7	MS. DONNA TAYLOR-KOLIS,
8	appeared on behalf of the Plaintiff;
9	
10	BUCKINGHAM, DOOLITTLE & BURROUGHS, LLP,
11	(4518 Fulton Drive, NW,
12	Canton, Ohio 44735-5548,
13	330-492-8717), by:
14	MR. STEPHEN P. GRIFFIN,
15	appeared via video teleconference
16	on behalf of the Defendants
17	Youn Park, M.D., and Y.W. Park
18	M.D., Inc.
19	
20	ALSO PRESENT:
21	(Via video teleconference)
22	YOUN PARK, M.D.
23	
24	REPORTED BY: JOANNE H. RICHTER, C.S.R. 84-2082.

E S Q U I R E[™]

).

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

1 BARRY WENIG, M.D., called as a witness herein, having been first duly 2 sworn, was examined and testified as follows: 3 4 EXAMINATION BY MR. GRIFFIN: 5 6 State your name for the record, please. Q. 7 Α. Barry Lloyd Wenig. 8 And your profession? 0. 9 Α. I am a physician. 10 Any expertise of any particular area? Q. 11 Α. Yes. 12 What area, sir? I don't have your --0. 13 Otolaryngology and head and neck Α. 14 surgery. 15 What positions do you hold Ο. 16 professionally currently? 17 I am professor of otolaryngology and Α. head and neck surgery at Northwestern University, 18 Feinberg School of Medicine and I am chief of 19 otolaryngology and head and neck surgery at 20 Evanston Northwestern Healthcare. 21 22 How long have you held those positions? Q. 23 I have been at Northwestern since Α. January 1, 1999. Same is true at Evanston. 24

UIRE

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

3

1 Q. Are you board certified? 2 Α. Yes, I am. З Q. In what area? 4 Α. Otolaryngology and head and neck 5 surgery. 6 When did you become board certified? Q. 7 Α. 1986. 8 Q. And this was your first testing 9 attempt --10 Α. Yes. 11 -- In otolaryngology? I guess I can see Q. your educational and employment history in full on 12 13 your CV, is that correct? 14 Α. That is correct. 15 0. Does your CV also include any publications that you have had through the years? 16 17 Α. Yes, it does. 18 Does it include any presentations you 0. 19 have made through the years? 20 Α. Yes, it does. 21 Q. Have you published anything with respect to squamous cell carcinoma of the nasal vestibule? 22 23 Α. Yes, I have. 24 Q. Can you tell me specifically by

UIRE[™] LINK

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

4

identifying those particular writings if you like by name or by number on your CV, so we can reference those that you feel have particular relevance to this case.

A. Yes, but I don't have my CV in front of me right now, so I couldn't tell you at this very moment, but I will get that information to you.

Q. Do you have, by recollection, any
articles in mind or any book chapters, et cetera,
that would be relevant to this case?

A. I recently -- I would say within the last two to three years -- wrote an article on -as a coauthor, on carcinoma of the nasal vestibule, but I don't recall specifically where it was published.

Q. You wrote it in the last two to three years so that would make it by the year 2000 or so? A. I would guess, yes.

19 Q. Do you represent that the material and 20 items that you wrote about in that 2000 article 21 would have been the standard of care in 1999 or the 22 year 2000?

A. Yes, I do.

Q.

Esquire

24

R

23

5

6

7

Is it usually typical for literature to

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

come out first before the standard of care is 1 adopted, to kind of catch up to the literature? 2 Not necessarily, no, but this was more a 3 Α. review article dealing with clinical presentation 4 of disease, etiology, general treatment modalities 5 for this type of carcinoma and survival data. 6 So I don't think it is terribly relevant that it came 7 out possibly a year, year and a half after the 8 9 events that we are discussing here. 10 Q. Other than the fact that it would not have been available to any clinician to utilize in 11 his practice unless they found the individual 12 13 studies that you cite? 14 Α. That's correct. 15 Are there any other articles off the top Q. of your head? You tell me you don't have your CV 16 17 there. 18 I will be very honest with you. Α. I've published close to 100 articles. I have written, 19 20 I think, 15 texts or parts of texts. I just can't recall everything that I have written, and my 21 memory is going as I get older, so I apologize. 22 23 Do you have any idea how many articles Ο. 24 Dr. Park would have written?

UIRE

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

Dr. Park is here, by the way. I don't 1 2 know if your camera can see him. 3 Do you have any idea how much he has 4 contributed to the literature? 5 Α. I have seen his CV, yes. So you are familiar with how much he has 6 Ο. 7 contributed to the literature? 8 Α. I have seen his CV, yes. 9 Q. What does that mean, "I have seen his 10 CV"? 11 Α. I commend Dr. Park on his efforts to publish, but the vast majority of Dr. Park's 12 13 publications are case reports dealing with isolated 14 clinical entities primarily in journals that are addressed to emergency physicians and family 15 16 practitioners. 17 Based on the CV that I had, Dr. Park published very few articles in the recent past 18 dealing in the otolaryngology literature in the 19 accepted peer review journals of our specialty. 20 21 That's not a knock on Dr. Park. 22 I commend him very much for being very academically 23 oriented, but in the traditional academic world, these articles would not be considered, how shall I 24

 $LSQUIRE \frac{Lm}{ch}$

R

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

say this, representative if someone submitted a 1 curriculum vitae such as Dr. Park's for clinical 2 status in an American university. 3 4 You have read his deposition, I assume? Ο. 5 Α. Yes, I have. 6 You are aware that he has recently Q. finished authoring a book about head and neck 7 8 cancers, correct? I know that he was in the process of 9 Α. writing a book and looking for financial support 10 for publication of the text, yes. 11 12 Okay. Very good. Dr. Wenig, what Q. caused the cancer in this patient? 13 14 Well, I can't tell you specifically what Α. caused it, but I can tell you that I am sure one of 15 the predisposing factors was Mrs. Bailes' use of 16 17 tobacco. 18 And do you find anywhere in the medical 0. records that there were discussions with her by any 19 physicians about quitting the use of tobacco or 20 21 abuse of tobacco? 22 I don't specifically recall seeing that, Α. but then again, I was fairly limited in my review 23 24 of physicians notes.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

8

R

Esqūire™

1 When you say you were fairly limited, Q. did that mean that you didn't want to read all the 2 records that were available on this patient, or did 3 you just look at Dr. -- what did you mean by that 4 statement? 5 6 Α. Whatever records were supplied to me, 7 that's what I read. All right. Did you read the entirety of 8 Q. Dr. Manning's chart? 9 10 Α. Yes, I did. 11 Then are you aware that on at least Q. three occasions, to my perusal over the last just 12 13 two minutes, that he had had discussions dating back to her in the early '90s about quitting the 14 15 abuse of tobacco? 16 That's very possible, yes. Α. 17 Would the failure to quit have 0. contributed to the cause or the commencement of the 18 19 cancer on behalf of the patient? 20 I don't know if anyone would be able to Α. answer that question for you. The best way that I 21 could answer it is to tell you that tobacco use is 22 one of the etiological factors in the development .23 of a carcinoma of the head and neck region. 24

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

SOUIRE

1 Is it the leading cause, to the 0. scientists' knowledge at this point in time? 2 What is the medicine on that currently, Doctor? 3 4 Α. It is one of the causes. A lot of studies dealing with carcinoma of the head and neck 5 region are generalized studies without 6 site-specific locations relating to both the use of 7 alcohol and tobacco. 8 I can't tell you specifically if this is 9 the only factor dealing with carcinoma of the nasal 10 11 septum. I think it is a multifactorial disease of which this is one. 12 13 This is a leading factor? Q. 14 I don't want to be argumentative, but Α. 15 what do you mean by "leading"? 16 Is it more of a cause, more of a known Q. cause to the carcinoma of the nasal septum than any 17 18 other cause? 19 I would say it is probably the most Α. easily identifiable cause. Whether --20 21 Were there any other -- excuse me, go 0. 22 ahead. 23 Α. Whether it leads or not, I can't specifically say. There are other factors. 24

LINKING TESTIMONY, TRADITION AND TECHNOLOGY

10

Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

Esqūire™

1 Q. Can you --Environmental exposure, toxin exposure, 2 Α. 3 things of that nature, yes. 4 Can you identify any other factor in Ο. 5 this plaintiff? Well, some people with a history of 6 Α. chronic rhinitis and chronic nasal irritation can 7 undergo a metaplastic process which could be a 8 setup for the development of carcinoma in the 9 10 future. 11 Now, what the triggering factor is at that point that converts from a benign condition to 12 a malignant condition, I don't think anyone has any 13 14 good way of knowing. 15 All right. Let me state it generally. Q. If the plaintiff had taken the advice of her 16 doctors and quit smoking, would that have been a 17 possible -- strike the way that question is worded. 18 19 If she had taken her doctor's advice and quit smoking, would that have reduced the chances 20 21 that she would have contracted this nasal vestibule 22 cancer? 23 Well, I think there is, certainly, a Α. temporal relationship between the cessation of 24

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

E s q ū i r e"

smoking and the chances of developing a carcinoma.
Clearly, had she stopped, for argument sake,
15 years before she developed the carcinoma, then
her chances of developing the carcinoma would have
been much less than had she stopped a year before,
for example.

50 I don't know specifically when she was advised about stopping, and since this is a prolonged process with respect to conversion from a benign to a malignant condition, logically speaking it makes sense that the chances would be less had she stopped earlier than later.

13 Q. Do you advise your patients to quit 14 smoking?

A. When I see patients who have -- let me
rephrase that. The majority of patients that I see
have either been diagnosed with carcinomas or I am
the one who diagnoses them with carcinoma.

19 It is not that I see patients who have 20 benign conditions or general ENT problems and they 21 tell me that they smoke and I tell them that they 22 should stop smoking.

On my cancer patients, either previously diagnosed or newly diagnosed, I explain to them

ESQUIRE

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

that smoking is one of the risk factors in the development of cancer of the head and neck region and I suggest to them that they consider stopping the use of tobacco because of the possibility of either getting a recurrence following treatment or developing a second primary tumor following treatment.

Q. So even in patients that have nasal carcinoma, you still recommend that they stop at that point in time that the diagnosis is made for purposes of recurrence?

A. Recurrence or development of a new tumor of the upper air or digestive track, yes. I think it is obligatory on the physician treating the patient to make the patient aware of the cause-and-effect relationship between cigarette use and head and neck cancer.

You can advise the patient and encourage the patient and make the patient aware of that, but you can't physically or forcibly make them stop. That's up to them, but --

Q. That's your medical advice?

A. Yes, it is.

E s q u i r e'

Q. A patient always has the option of

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704 4950

R

22

23

following your medical advice or disregarding your 1 medical advice, I think is the point you are 2 3 making? 4 Α. That's correct. 5 Doctor, how did you end up with this Q. 6 case? 7 I was contacted by Ms. Taylor-Kolis who Α. asked me if I would look at the materials involved 8 9 in this case. 10 And you received a telephone call from 0. 11 Ms. Kolis? 12 Generally speaking, that's what Α. 13 happened. I can't remember the specifics of this case, but that's usually what happens. 14 15 Have you kept a file concerning this Q. 16 case? 17 Α. Yes, I have. 18 Have you kept all the letters that you Q. received from the attorney? 19 20 Α. Yes, I have. 21 Do you know when the first letter that Q. 22 you received from the attorney was? 23 If you will give me a moment, I will Α. look and see if I can find it. I am not doing a 24

ESQUIRE[™] Linking Testimony, Tradition and Technology

Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

good job of finding it at this point. Let's see, 1 2 yes, July 25th, 2002. 3 MR. GRIFFIN: I just want to put something on 4 the record, Doctor. Excuse me a second. I am going to ask that all correspondence within the 5 file of Dr. Wenig be produced. 6 7 BY MR. GRIFFIN: 8 Dr. Wenig, this first letter, could you Ο. briefly preview that for me? This is a starting 9 point for my questions. 10

A. Sure. It is a letter from
Ms. Taylor-Kolis to myself -- I am sorry, from
Thomas Conway to myself, where Mr. Conway said that
he represents the family of Geraldine Bailes.

She was diagnosed with a squamous carcinoma in January 2001. She received radiation therapy and chemotherapy and subsequently died approximately one year later.

19She had been seen by Dr. Park from20August 1986 until September of 2000. She had also21been treated by Dr. Manning. And subsequently22following her treatment by Dr. Park, she was23treated by Dr. Steinberger, who made the diagnosis.24And then there is a list of things that

Esqūire™

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

are enclosed for my review and he asked me at that 1 point to determine if Dr. Park or any other medical 2 provider deviated from the standard of care and 3 determine, if that was -- if there was a deviation, 4 was that the proximate cause of Mrs. Bailes' death. 5 6 That would have been presumptuous for Q. him to send you a letter with a stack of medical 7 records without having had a conversation or a 8 commitment from you that you were willing to review 9 10 the case, correct? 11 Α. That's correct, yes. 12 So you think you probably got a 0. 13 telephone call first? 14 Α. I assume I did, yes. 15 Just out of the blue, or did you know Q. Mr. Conway or Ms. Kolis from prior occasions? 16 17 No, it was out of the blue. Α. 18 This case wasn't assigned to you by any Q. 19 medical expert service? 20 Α. No, it was not. 21 Somehow they came up with your name and Q. 22 you don't know how? 23 To the best of my knowledge, I really Α. 24 have no idea how.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

ESQUIRE

R

1 Q. Have you ever testified in the state of 2 Ohio on prior occasions, either at trial or given a deposition for a case that was pending in the state 3 4 of Ohio? 5 Α. I don't recall specifically. I think 6 not. 7 Do you advertise your expert services at Q. all, Doctor? 8 9 Α. No, I do not. 10 Do you work for any medical expert Q. service, in other words, a service that is able to 11 12 locate an expert, kind of brokers between an 13 attorney and the expert based upon what the case 14 needs? 15 I don't work for any services, no. I am Α. listed with two -- three services as someone who 16 would be willing to review cases, but I don't work 17 18 for them. 19 I understand. How did your name get on Q. 20 these three lists? 21 I was contacted by each one of the Α. services to review -- to ask me if I would be 22 willing to review a case, and once I reviewed one 23 case, they kept me on the list as a possible 24

17

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

Esquire™

1 || reviewer.

ESQUIRE[™]

R

-	Lovience.
2	Q. Do you know the name of the services?
3	A. Yes, one is Pennsylvania Physicians for
4	Legal Review, one is Medquest, and one is something
5	American Forensics or something to that nature.
6	Q. How many cases do you currently have
7	that you are reviewing and rendering expert
8	services?
9	A. I get approximately, I would say, about
10	20 contacts a year from various and sundry
11	individuals whether I would be willing or not to
12	review a case. If I am not willing to review the
13	case for whatever reason, I will tell them right on
14	the spot. If I tell them based on the summary they
15	give me that the case doesn't appear to have any
16	merit to me, I will tell them that on the spot.
17	I wind up with about, I would say, 10
18	cases, 10 to 12 cases a year to review, actually to
19	review the case, and I think that's about a good
20	number I mean, a reasonable number for a year.
21	Q. How many do you have open currently?
22	A. I couldn't even begin to tell you.
23	Q. Your best estimate.
24	A. I would guess probably around 15.

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

1 Of those 15, how many are you testifying Q. on behalf of a plaintiff? 2 3 Α. Half. 4 When is the last time you gave testimony Ο. on behalf of the physician's standard of care? 5 6 I don't understand what you mean. Α. 7 When is the last time you rendered Ο. testimony either by deposition or live in court on 8 behalf -- in support of the standard of care of a 9 10 physician? 11 That means to defend a physician, is Α. that what you are saying? 12 13 Q. Yes, sir. 14 I just wanted to clarify that. I wasn't Α. 15 sure what you were saying. 16 Ο. Sure. 17 Well, I know I have done two this year, Α. but I can't recall specifically when, what month it 18 19 was. 20 By way of deposition or court Q. 21 appearance? 22 I don't think I have been to court this Α. 23 year. By deposition. 24 Q. Can you remember the names of the

R

Esoūire™

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

1 physicians?

2	A. One is Brian Farrell here in Chicago.
3	Q. The other?
4	A. I can't recall. I just got a case last
5	week in defense of a physician, but I can't
6	remember the other one.
7	Q. Yes, sir. And Dr. Farrell's case, what
8	type of case was that? What was the general
9	allegation made against Dr. Farrell?
10	A. It was a case of obstructive sleep apnea
11	and the patient died following the surgery.
12	Q. And the other case that you cannot
13	recall the doctor's name?
14	A. I am sorry, I just can't remember.
15	Q. Can you recall ever an occasion where
16	you appeared in court at trial to testify on behalf
17	of a physician's standard of care?
18	A. Yes.
19	Q. In support of the standard of care?
20	A. Yes.
21	Q. How long ago was that?
22	A. I have been to court, to the best of my
23	recollection, three times to testify on the
24	standard of care on behalf of a physician. The

R

E S Q U I R E^M

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

most striking one that I remember, because it was 1 here in Chicago is John McMahon was the physician, 2 and that was about, I would guess, eight or nine 3 years ago. I am sorry, I don't specifically recall 4 5 the case -- the other cases. 6 Q. The name of the attorney that represented Dr. Farrell, do you recall his name? 7 8 Α. No, I don't. 9 Q. Or his law firm? 10 Α. I don't. 11 Okay. Currently, what are your charges Q. for your expert services, Dr. Wenig? 12 13 I charge \$400 an hour for review of Α. materials and \$500 an hour for deposition time or 14 preparation time for depositions. 15 16 What is your trial charge? Q. 17 Out of Chicago it is \$5,000 a day plus Α. 18 travel expenses. 19 Do you have plans to come to Ohio the Q. week of September 8th for this trial? 20 21 I don't have any plans. If I need to I Α. will, but I would prefer not to. 22 23 Doctor, have you reviewed the entire Q. 24 chart of Dr. Park?

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

21

R

Esoūire™

1 Α. Yes, I have. 2 Certainly, you don't believe this woman Q. had cancer in 1986, nasal carcinoma, do you? 3 4 Α. No, I do not. 5 0. Then do you believe that Dr. Park's treatment and care that was rendered for a period 6 7 of time for sinus problems, or chronic sinus, or rhinosinusitis, or those conditions through the 8 late '80s, that care was appropriate and to the 9 standard of care? 10 11 Α. Yes, I do. 12 Moving into the 1990s, Dr. Park treated Q. 13 this patient for impacted cerumen and continued to treat her for nose and sinus problems and 14 rhinosinusitis and vestibulitis. 15 16 Did his care and treatment up to 1993 meet the appropriate standard of care applicable to 17 physicians in his field of practice? 18 19 Α. Yes. 20 So up until 1993, at least, you believe Q. 21 Dr. Park had an ability to conduct examinations, 22 identify problems, and treat them appropriately, 23 correct? 24 Α. That's correct.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

E s q ū i r e™

1 And an ability to recognize and treat 0. vestibulitis and rhinosinusitis, correct? 2 3 Α. Yes. 4 He demonstrated that to you by virtue of Q. his care and treatment selected and the resolution 5 of her problems, correct? 6 7 Α. Yes. 8 And for the record, Doctor, can you Ο. define for us what vestibulitis is? 9 10 Α. It is an inflammatory process of the nasal vestibule, which is, generally speaking, 11 secondary to an infection of one of the hair 12 follicles within the nasal vestibule usually as a 13 result of the bacterial organism staph aureus. 14 15 What is the typical complaint, the Q. presenting complaint that the patient makes for 16 17 this condition? 18 Some soreness, some pain, usually they Α. feel a pimple or a bump, sometimes there is some 19 discharge in the area. Those are the typical 20 21 complaints. 22 And I know this probably isn't the rule, Q. but if untreated, is it possible for this condition 23 24 to last indefinitely?

E s o ū i r e'

R

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

1 Generally speaking, it doesn't last Α. indefinitely. It will resolve eventually. 2 What that time frame is, I really can't answer it for 3 you. But most things of this nature would resolve. 4 5 They would be very bothersome to the patient after a while, so I would assume they would 6 seek treatment, but if you leave anything alone 7 long enough, it generally goes away unless it is 8 9 something that's a chronic issue.

Q. In some cases the symptoms can be very minimus and mild, I suspect, but in other cases the symptoms can be more severe, correct?

A. They can be a little more dramatic. The
pain is a little more intense, yes, but that's
pretty much about it.

Q. Is it possible for ulcers to develop on occasion on a more severe presentation of nasal vestibulitis, in your opinion?

A. In my opinion, no.

ESQUIRE

20 Q. Do you know if it has been reported in 21 the medical literature, to your knowledge?

A. To the best of my knowledge, I can't --23 I cannot tell you because I don't know every 24 article that's been written about nasal

R

1 vestibulitis.

2 I am certain you try to stay up to date Q. with the current literature to the extent you can, 3 and my question is geared toward that type of 4 5 literature. I don't recall seeing that as a 6 Α. presenting symptom in nasal vestibulitis. 7 8 I am going to move forward then to 1996, 0. where Dr. Park treated this patient for nasal 9 hypertrophy of the turbinates and rhinopharyngitis, 10 11 January 5 of 1996. 12 Did his care and treatment on that date meet the standard of care, in your opinion? 13 14 For her condition at that time, yes. Α. 15 On February 17 of 1997, the plaintiff Ο. complained of sinus infection, was on antibiotics, 16 with her ears stopped up, and again he treated her. 17 18 Was his care and treatment on February 17, 1997 to the standard of care in your 19 20 opinion? 21 Α. Yes. 22 Doctor, in your opinion to a medical Q. degree of -- well, to a reasonable degree of 23 medical probability, was there nasal carcinoma 24

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708 8087 • Fax 312 704 4050

R

E s o ū i r e"

present in February of 1997 in the plaintiff? 1 2 Α. No. On September 4 of 1998, the plaintiff 3 Q. presented to Dr. Park's office and was treated for 4 rhinosinusitis, as well as the septal deviation. 5 6 She had her ears cleaned out. 7 Did his care and treatment on that date meet the standard of care, in your opinion? 8 I just want to make one minor 9 Α. correction, if you don't mind. It's semantics. 10 11 She was not treated for septal deviation. She was identified as having an septal deviation. 12 13 Right. With that correction, did his Q. care and treatment meet the standard of care on 14 15 September 4 of 1998? 16 Α. Yes. 17 Was there a nasal carcinoma present, in Ο. your opinion, to a reasonable degree of medical 18 probability, in September of 1998 in the plaintiff? 19 20 Α. No. 21 I want to jump forward to November 15 of 0. 1999. According to my records, that is the next 22 opportunity Dr. Park had to treat this patient. 23 24 Is that a correct assumption on my part

R

ESQUIRE

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

based upon the records you have in front of you? 1 2 Α. Yes, that is correct. 3 So over one year later she presents to Q. him with a complaint of "sore nose, ear plugged, 4 cheek hurts, sore," do you see that? 5 6 Α. Yes. 7 Now, Dr. Park made an illustration on Q. that particular office visit, did he not? 8 9 Α. Yes. 10 Did you see any such illustration in Q. Dr. Manning's chart prior to that visit with 11 12 Dr. Park? 13 No, I did not. Α. 14 Do you have any knowledge, Doctor, 0. whether or not Dr. Manning ever even telephoned 15 Dr. Park concerning his findings or concerns at any 16 time in this case as it unfolded? 17 18 To the best of my knowledge, there was Α. no contact between Dr. Manning and Dr. Park. 19 20 All right. Do you know whether or not Q. Dr. Park ever knew that the patient was even being 21 informally referred by Dr. Manning for any reason? 22 23 I have no way of knowing that. I would Α. 24 guess not.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

R

ESQUIRE

1 You have reviewed Dr. Park's chart. Q. You know that Dr. Manning's chart is not a part of 2 Dr. Park's chart, correct? 3 4 Α. Correct. 5 You have seen Dr. Manning's chart and Ο. 6 you know there was no letter that was ever authored by Dr. Manning indicating any concern or finding to 7 Dr. Park, correct? 8 9 Α. Correct. 10 All right. Now, Dr. Park had an Q. 11 impression of rhinosinusitis and vestibulitis on November 15 of 1999, correct? 12 13 Α. Correct. 14 Did Dr. Park meet the standard of care Ο. in his care and treatment of the plaintiff on 15 November 15 of 1999? 16 17 Α. No. 18 And tell us why? Q. 19 Dr. Park, by his own diagram, diagnosed Α. a crust on the left side of the nose. And 20 crusting, in my opinion, is not an appropriate 21 22 finding for the diagnosis of vestibulitis. 23 Doctor, how do you define "crust"? Q. 24 Α. The same way everyone else does.



LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800 708 8087 • Fax 812 704 4050

28

1 How does the medical literature define Q. 2 "crust"? 3 It is a collection of congealed debris Α. over an area of irritation or inflammation. 4 5 Does any medical literature define it as <u>Q</u>. 6 dried mucous? 7 I could say that dry mucous is a Α. component of crusting in the nose, yes. We are 8 talking about the nose? 9 10 I am not asking you whether it is a Q. component. I am asking you whether or not some 11 define "crust" as dried mucous, whether that is 12 13 found in the medical literature, or whether that is common terminology used among your peers? 14 15 You cannot have dried mucous unless you Α. have an underlying condition that causes the mucous 16 to dry up and crust in that area. So on the one 17 hand, your supposition is correct. It is dried 18 mucous. But on the other hand, there has to be a 19 20 reason why there is dried mucous. It just doesn't 21 happen. 22 Doctor, I have dry mucous in my nose Q. 23 right now. Does that mean I have an underlying 24 carcinoma-type condition causing that?

R

ESQUIRE

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

I didn't say it is necessarily 1 Α. carcinoma. I said an underlying change in the 2 standard or normal condition of the nose, yes. 3 4 You could have, living in Ohio, sinus disease and that's enough to change the mucosa of 5 the nose and you can have some crusting there, yes. 6 7 So everybody that has a dried crust or Q. dried mucous in their nose -- strike that. 8 What should have Dr. Park done on 9 10 November 15 of 1999? 11 I think at that point he should have Α. been aware that something other than his previous 12 diagnoses of vestibulitis is potentially going on, 13 and that he should treat the patient with local or 14 topical medication and see if this crusting would 15 16 resolve. 17 He did treat the patient with a cream, Ο. 18 did he not? 19 Α. Yes, he did. 20 Was that the appropriate cream? Q. 21 For that condition, yes. Α. 22 Well, then he met the standard of care Q. 23 in prescribing the cream? 24 Yeah, I don't have any problems with Α.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4850

30

R

E s q u i r e'

1 that.

4

5

6

7

8

21

22

23

24

2 Q. Then Dr. Park met the standard of care 3 on November 15, 1999?

A. By that definition, yes.

Q. There is nothing as far as symptoms presenting on November 15 of 1999 that there was bleeding, correct?

A. No, I didn't see any of that, no.

9 Q. And no ulcer advancing to necrosis on 10 that visit, correct?

A. Well, I can't answer that question because the crusting could certainly have obscured an ulcer advancing to necrosis. I mean, crusting, as I told you, crusting just does not happen in and of itself.

Q. Well, Doctor, I guess we can talk about that more later. Let me finish my questions here.

Was there any mass that was identified at any point in time by Dr. Manning or Dr. Park up to November 15 of 1999?

A. How do you define a mass?
Q. How do you define a mass?
A. I asked you first.

E s q u i r e

Q. It doesn't matter how I define it. It

LINKING TESTIMONY, TRADITION AND TECHNOLOGY

makes no difference how I define it. 1 It matters 2 how you define it. 3 Based on the notes that I saw from Α. Dr. Park and Dr. Manning, there was no description 4 of a mass on any of the visits up to that point. 5 6 Was there any presentation by the Q. 7 plaintiff that complaint of losing weight? 8 Α. No. 9 Q. Any nodule? 10 Nodule? Α. Where? 11 Anywhere in the nasal vestibule or Q. 12 surrounding area. 13 Not by description, no. Α. 14 Any satellite lesions? Q. 15 Not by description, no. Α. 16 Was she complaining of extreme pain? Q. 17 No, just some discomfort. Α. 18 Did she have any deforming points to her Q. nose at that point in time? 19 20 Α. No. 2'1 Wouldn't all the signs and symptoms I 0. 22 have just gone over been hallmark signs for increasing suspicion for nasal carcinoma? 23 24 Α. They are among them, except for the ones

32

R

ESQUIRE

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4050

that the patient did have, which you didn't 1 2 describe. 3 Q. Pardon me? 4 The patient did have one that is a Α. 5 classical finding, which you didn't mention, and 6 was seen --7 Dried mucous? 0. 8 Α. No, the ulcer. 9 Q. What was it? 10 The ulcer that Dr. Manning found. Α. 11 Dr. Manning found an ulcer. Was there Q. any notation in Dr. Park's records that he found an 12 13 ulcer? 14 No. He found some crusting over the Α. 15 ulcer. 16 But you are saying, then, that there Q. was -- you are making the assumption, Dr. Wenig, 17 that there was an ulcer under this crusting, 18 19 correct? 20 I am making that assumption. That's the Α. basis for my opinion. 21 22 And without that assumption, your whole Ο. opinion fails, doesn't it? 23 24 Α. That's correct.

LINKING TESTIMONY, TRADITION AND TECHNOLOGY

Chicago: 312.782.8087 • 800 708 8087 • E-

33

R

E s o ū i r e"

1 Okay. So let's move on then. 0. I think 2 we have covered November 15. 3 The next date is November 23 of 1999. Dr. Park saw her again eight days later in his 4 office. You had mentioned previously that 5 Dr. Park should have been watching her. Was eight 6 days to return to his office an appropriate amount 7 of time to have her back? 8 9 Α. Yes. 10 Would that suggest that Dr. Park was 0. increasing his surveillance of the patient and the 11 12 patient's condition? 13 Α. Yes. 14 Does his record show any signs of Ο. finding any ulcerated area? 15 16 He makes no mention of it, no. Α. 17 Is your opinion that there was something Ο. that he missed on examination on November 23 of 18 19 1999? 20 Α. Yes. 21 What did he miss, Dr. Wenig? Q. 22 Α. The carcinoma of her nasal vestibule. 23 How do you know that, to a reasonable Q. degree of medical probability, without making a 24

ESQŨIRE[™]

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

1 || flying assumption?

ESQUIRE®™ DEPOSITION SERVICES

	_
2	A. Because when she was diagnosed with
3	carcinoma, she was diagnosed with a carcinoma that
4	arose in this area. And if you hear hoof beats, it
5	is generally not zebras. And cancer shows up where
6	it is located, and this is the exact area that was
7	described by Dr. Manning as the ulceration. It is
8	the exact area that Dr. Park identified crusting
9	over what I believe was an ulceration, and this is
10	where the cancer was eventually, and this is where
11	it arose. And that's why I am saying that
12	Dr. Park missed the cancer that arose in the nasal
13	vestibule.
14	
	Q. Does cancer grow at a continuous
15	progressive rate?
16	A. Yes.
17	Q. You don't see signs of continuous
18	progressive rate of growth from November of 1999 to
19	the point of identifying by biopsy this cancer, do
20	you, Dr. Wenig?
21	A. It went from a smaller area to a larger
2.2	area. That is a programmed
23	growth rate for different cancers is different.
24	
67	Some grow faster than others. This is a
1	

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

particularly slow-growing cancer. 1 2 Q. But we can rest assured that physicians in the area of treating cancers know that cancers 3 don't wax and wane, do they? They don't appear and 4 5 disappear, do they? 6 Α. No, they do not. 7 And your review of Dr. Manning's chart Ο. would suggest even the area that he identified as 8 being an ulcer was waxing and waning and seeming to 9 10 improve? 11 Well, that doesn't mean that there are Α. areas of the underlying condition that can improve. 12 There is an inflammatory process around the primary 13 process, and with certain types of treatment like 14 the aquaphor that she was treated with by 15 Dr. Manning, and like the bacitracin that she was 16 treated with by Dr. Park, you can eliminate the 17 inflammatory component, but the underlying cancer 18 19 component remains. 20 When you look at it as an overall picture, yeah, it may look a little smaller because 21 you have treated a portion of it and that's 22 responding, but the basic problem remains. 23 It is not that the cancer waxes and wanes. 24 The cancer

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704 4950

R

ESQUIRE
1 remains and grows.

E S Q U I R E^M

R

	- Smarins and grows.
2	Q. Because we can rest assure that when you
3	testify you will be telling the ladies and
4	gentlemen of this jury cancer does not wax and
5	wane, it continues at a progressive rate?
6	A. That's correct.
.7	Q. What is the difference between a
8	recurrent ulceration and a chronic ulceration as
9	used by Dr. Manning?
10	A. A recurrent ulceration is one that I
11	don't know how Dr. Manning uses it. I am going to
12	define how I would use it. A recurrent one is one
13	that was there, went away, and came back again.
14	Chronic ulceration is one that remains.
15	It may not be as large or significant as it was
16	when it was initially diagnosed, but it still does
17	remain, at least to some degree.
18	Q. All right. Recurrent ulceration would
19	be less concerning than a chronic ulceration, in
20	your opinion, then?
21	A. Well, to be quite honest with you, the
22	answer to that question is no, because we are,
23	after all, human beings and when we evaluate
24	something as physicians we may not be able to

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4050

1	appreciate the full extent of the condition.
2	And Dr. Manning or myself or any other
3	person, for that matter, may look at a problem and
4	say, "Yeah, it looks like it is almost all gone."
5	And then a while later it will come back
6	and we will say, "Well, now it is recurrent" as
7	opposed to being chronic, because we didn't
8	appreciate that it was not completely gone. So it
9	is very difficult for me to say what was in the
10	mind of somebody calling it recurrent or chronic.
11	Q. Well, just answer this question for me,
12	then. Why does medicine make a differentiation
13	between recurrent and chronic ulceration? Why is
14	there differentiation?
15	A. Because in an ideal world, which we hope
16	medicine is, when we know it is not, there is a
17	difference between the two, and that we are good
18	enough to tell the difference.
19	Q. Excuse me. So when a physician uses the
20	term "recurrent ulceration," that is different than
21	the word "chronic ulceration"?
22	A. It should be, but again
23	Q. It should be?
24	A. We don't always make that distinction.

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704 4950

38

R

ESQUIRE[™] DEPOSITION SERVICES

1 And the differentiation is that 0. recurrent ulceration is less concerning for a sign 2 of potential cancer than chronic ulceration? 3 4 Yes, that is correct. Α. 5 I mean, anybody can have an ulceration 0. in their nose just from picking their nose or from 6 over rubbing it with a handkerchief? 7 8 Α. That's true. 9 Q. A large majority of the population will have ulcerations in their nose from time to time 10 based upon what their habits are? 11 12 I don't know about the large majority, Α. but a certain percentage will, sure. 13 14 Did Dr. Park meet the standard of care 0. on November 23, 1999 based upon his office note? 15 16 Α. You have put me in a very difficult 17 decision. To be very frank with you, I think his 18 office note is lacking in the sense that I think 19 that he did not appreciate what was going on and he recorded what he did appreciate, but in my opinion, 20 this was -- it was not an appropriate appreciation 21 of the condition at that point, so --22 23 0. I see. 24 Α. So --

R

E s o u i r e™

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800 708 8087 • Fox 212 704 4050

Q. Although he had been treating her appropriately and to the standards of care since 1986, suddenly in November of 1999 he falls off the other end in failing to meet the standard of care --

A. Yes.

Esquire™

6

7

8

9

Q. -- and not understanding or knowing his patient, his long-term patient, that's your opinion?

A. Not understanding or knowing the problem
11 that his long-term patient had.

Q. But you would agree that if all he found was dried mucous and some swelling and some septal thickening, that those were not signs or symptoms of an underlying cancer for which he needed to be alerted and obtain a biopsy?

17 In an isolated environment, in and of Α. themselves, I would answer your question saying no. 18 Given his previous history the week before, having 19 been seen, having the bacitracin treatment, having 20 no response whatsoever over the week, describing a 21 new finding of nasal thickening and erythemia, 22 23 which was never described by him before, all those 24 things add up to me to him not having met the

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

R

standard of care in this particular instance. 1 2 What is nasal hypertrophy? Q. 3 Α. If you are referring to turbinate hypertrophy, it is swelling of the turbinates, 4 mucosa overlying the turbinates. 5 6 Q. Is that septal thickening? 7 No, the septum is a different anatomical Α. 8 area than the turbinate. 9 Doctor, let's move to September 5 of Q. 10 2000. That is the last time Dr. Park ever had an opportunity to see this patient, is that correct? 11 12 Α. That's correct. 13 So in other words, from November 23 of Q. 1999 until September 5 of 2000, this patient never 14 15 presents to Dr. Park with any type of claim or problem of ulceration or pain or bleeding or 16 17 anything, correct? 18 That's correct. Α. 19 And on the presentation of September 5 Ο. of 2000, she is complaining of a sore nose, 20 according to Dr. Park's office record, correct? 21 22 Yes, that's what Dr. Park wrote, yes. Α. 23 He found a mouth lesion at that point in Q. 24 time, correct?

R

ESQUIRE

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

1 He found what he described as a mucosal Α. 2 lesion, yes. 3 A right buccal lesion, correct? 0. 4 That's the description, yes. Α. 5 And it was his intent and ordered on a Q. surgery schedule form an excision of that lesion, 6 7 correct? I don't know if it was excision, but 8 Α. certainly a biopsy of the lesion, yes. 9 10 And the patient canceled that biopsy 0. that he had requested in September of 2000, 11 correct? 12 13 Yes, to the best of my knowledge, yes. Α. 14 Do you do biopsies in your office? Q. 15 Α. Yes. 16 When you do a biopsy, do you scope your Q. patient's ear, nose and throat? 17 18 Depends what I am doing the biopsy for. Α. 19 Let's say you are going to do a biopsy Q. of the right buccal lesion. 20 21 Well, is this the first time I am seeing Α. the patient? Is the patient coming back for a 22 scheduled biopsy, because all of that is important, 23 because I generally do a scope on the patient the 24

ESQUIRE

R

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

first time I see them, so --1 2 Let's do it in the circumstances that 0. present here in September of 2000. He sees a 3 lesion in her mouth, notes a lesion and shows an 4 inclination to biopsy a lesion, correct? 5 6 Α. Okay. With the suspicion of carcinoma, is that why he is doing the biopsy? 7 8 You have read his deposition. Q. I am not here to testify for Dr. Park. 9 10 Α. Okay. 11 Now, this would be the first finding of Q. 12 any lesion by Dr. Park at any time since 1986, 13 correct? 14 Α. Yes. 15 And it also shows an inclination on his Q. behalf to go ahead and perform biopsies of lesions 16 he identifies, does it not? 17 18 Α. Yes. 19 And that suggests he understands the Q. standard of care with respect to identifying a 20 lesion and having it biopsied, correct? 21 22 In this particular instance, yes. Α. 23 Now, under these circumstances, would Q. you have also scoped the patient when you were 24

R

E s q ū i r e'

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

conducting an excision or performing the biopsy? 1 2 Well, I tried to answer that question Α. for you. I wouldn't have taken the patient to the 3 operating room to do a buccal mucosal biopsy. 4 Ι think that's an unnecessary procedure. 5 6 I would have scoped the patient in my 7 office at some point in the course of my evaluation of that patient, whether it would be at the time 8 that I biopsy the patient or at a time prior to 9 biopsying the patient when I first saw the patient, 10 but I would certainly not put the patient under 11 general anesthesia to scope them in the operating 12 13 There is no reason for that when you are room. biopsying a buccal lesion. There is no reason to 14biopsy them in operating room setting when you 15 biopsying a buccal lesion. There is no sense in 16 17 it. 18 MR. GRIFFIN: One moment. 19 (WHEREUPON, discussion was had 20 off the record.) 21 MS. TAYLOR-KOLIS: Let the record reflect that the Mr. Griffin went off the record to talk to the 22 23 doctor. 24 MR. GRIFFIN: Still here. Thank you, I am

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

R

ESQUIRE

1 || back.

2 BY MR. GRIFFIN:

Q. Dr. Wenig was making the assumption that this patient would be put under some sort of anesthesia.

6 If it was just being done by a local, 7 you wouldn't have a problem with that, would you, 8 Dr. Wenig?

9 A. Why do you have to take them to the 10 operating room to scope them?

Q. Are you saying this is out of the standard of care to do that, or is that an exercise of caution?

Let me ask you this, Doctor. Are we arguing over nothing here, or is that part of your standard of care criticism that he was planning on doing a biopsy procedure on this patient? Do you have a criticism, or is this just --

A. No, I have no criticism about his biopsy of the buccal mucosal. I am just disputing the issue of the scoping. I have no idea why he would want to scope her in the operating room.

Q. All right. Let's say he does, would you find criticism with that?

Esqūire™

R

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

1 Well, you have to tell me what kind of Α. 2 scope he wants to do. 3 Let's just say a scope of the ear, nose Q. 4 and throat. 5 You don't scope the ears. You look at Α. them in your office. You can scope the nose and 6 7 the throat in your office. 8 Could you explain to me the advantage of scoping the patient in the operating room other 9 than charging more money for it? 10 11 Dr. Wenig, all I am asking you is, is it Q. possible for a physician to do a scope procedure 12 along with conducting the biopsy -- I am not asking 13 you to bulge your veins out in your neck in yelling 14 at me. I am just asking you a simple question. 15 16 I am not asking you to ask me a 17 question, Dr. Wenig. I am inviting you to answer 18 mine. That's all. 19 MS. TAYLOR-KOLIS: I am going to object to your commentary. The doctor's veins are not 20 21 bulging out of his neck. He is trying to understand what you are asking him. Move along. 22 23 MR. GRIFFIN: If I had a videotape, that's precisely what's going on. 24

UIRE

R

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

1 BY THE WITNESS:

E s q ū i r e™

R

2 Α. To answer your question, a patient can be biopsied and scoped under local anesthesia in an 3 office setting, and a patient can be biopsied and 4 scoped under local anesthesia in a nonoffice 5 6 setting. 7 BY MR. GRIFFIN: 8 All right. This patient canceled the Ο. biopsy for whatever reason, correct? 9 10 Α. That's correct. 11 Dr. Park never had an opportunity to 0. conduct a biopsy of this lesion because of the 12 patient canceling the procedure, correct? 13 14 Α. Correct. 15 We will never know what Dr. Park would 0. have done or found if he had done this biopsy in 16 September of 2000 as he intended, correct? 17 18 Related to this particular lesion, Α. 19 correct. 20 When this cancer was diagnosed Q. 21 eventually, what was it staged? 22 Α. It was --23 Q. By Dr. Sider? 24 It was staged as a T1 lesion of the Α.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

1 nasal vestibule.

Q. Do you know of any study concluding the cancer mortality stage of disease is the result of an initial professional diagnostic delay?

A. I don't understand your question. Could
6 you repeat it, please.

Q. Sure. I am asking you, if she was a Stage 1, do you know of any study that has been performed in your field that would relate mortality of the Stage 1 cancer to a physician delay in diagnosis?

A. Before I answer your question, I need to understand a little better. Are you asking me is there a study in the literature that says that if you have a T1 cancer and you delay the diagnosis and it becomes a later stage cancer, then the mortality is greater than if you make it earlier?

18 I don't understand specifically what you 19 are asking me about "study."

20 Q. Let's have the court reporter read it 21 back.

A. I understand the English. I don't understand the intent of the question. I don't understand what you are asking me to respond to.

ESQUIRE

48

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

1 The language I understand. 2 Patient was a Stage 1 when diagnosed, Q. 3 correct? 4 Α. Correct. 5 Q. The patient died, correct? 6 Α. Correct. 7 So Stage 1 mortalities, do you know of Q. 8 any studies, Doctor, in the wealth of reading that you have done, that relate mortality to physician 9 delay -- initial physician delay in diagnosis of 10 11 Stage 1 patients? 12 Off the top of my head, I don't know Α. 13 any, no. 14 Are you familiar with the median waiting Q. time from the referral after biopsy to the start of 15 radiotherapy in the United States for treatment of 16 17 cancer? 18 Α. Yes. 19 Q. What is it? 20 Α. In between three and four weeks. 21 Are you familiar with any studies that Q. have found the median referral time to be ten days 22 23 in the United States? 24 Are we talking about referral to see a Α.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800 708 8087 • Fax 212 704 4050

Ŕ

E s o ū i r e*

radiation therapist or starting the radiation? 1 2 From the referral to the start of Q. 3 radiotherapy. 4 From the referral to the start being ten Α. 5 days? 6 Q. Yes, sir. 7 I find that to be a little questionable. Α. Most times it takes a little longer than that to 8 get things set up. That's why I said three weeks. 9 10 Q. What was it in Mrs. Bailes' case, from the referral to the start of radiotherapy? 11 12 I would have to look up that Α. 13 information. 14 Q. I believe the date her treatment started 15 was March 13 of 2001. 16 Α. Okay. 17 We see the consultation sheet of Q. February 14 of 2001 to Dr. Sider from 18 Dr. Steinberger. 19 20 That would make it around a month, then, Α. 21 right? 22 Q. Yes, sir. 23 Α. Okay. 24 Do you believe that there was an undue Q.

50

R

ESQŪIRE[™]

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704 4950 1 delay?

A. No, I just told you. It usually takes
about three to four weeks.

Q. Is delaying radiotherapy associated with
a decrease in survival, to your knowledge,
generally speaking?

A. Well, I think depends on how much you
delay. If you delay a year, yes. If you delay a
month, no.

Q. What would be a delay in -- an undue delay in your opinion? It is obviously greater than a month.

A. I would say around six to eight weeks.
Q. So, what, about the four to six weeks,
is that the period in between where you don't have
an opinion of whether or not that's delay?

17 No, I don't think that that's a delay. Α. I have an opinion. Generally speaking -- for 18 example, in patients who receive combined therapy, 19 which is, for example, surgery followed by 20 radiation therapy, we know that the radiation is 21 much more effective within six weeks of the surgery 22 than it is if we wait longer than six weeks. So we 23 24 try and get that done in that four- to six-week

E s q u i r e

R

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4850

range to start radiation. 1 2 Is delay in initiating radiotherapy Q. associated with a higher local failure rate in head 3 4 and neck cancer? What is "delay?" I told you --5 Α. 6 You have defined it as six to eight Q. 7 weeks. 8 Right. That's what I am saying. Α. 9 Others may define it is a much shorter Q. than that. You would acknowledge that, wouldn't 10 11 you? 12 No, I don't think that that's a delay. Α. I think that, realistically speaking, by the time 13 people get up and running and get simulated and get 14 prepared for radiation, people, meaning patients 15 and treating physicians, it is usually around four 16 17 to five weeks. 18 So you would expect that six weeks or so would be the upper limit of the time you want to 19 wait to start the radiation. Anything more than 20 that would be considered a delay. Anything less 21 than that would be certainly within the framework 22 23 of acceptability. 24 If I were to pull Dr. Wenig's charts, Q.

ESQUIRE

R

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

what is your period that you shoot for as far as 1 initiating radiotherapy? 2 3 As a primary modality alone? Α. 4 Q. Similar to this case. 5 Α. Within four --6 Q. This was her --7 Within four weeks. Α. 8 And are you comfortable with that with Q. your patients, four weeks, or do you try to get 9 10 them in earlier? 11 Get them in earlier and starting Α. radiation are two different things. I am talking 12 about starting radiation within four weeks. I am 13 not talking about getting them in to see the 14 15 radiotherapist. 16 Q. I am talking about starting 17 radiotherapy. 18 The answer to your question is four Α. 19 weeks is acceptable for me. 20 If it was your wife, would four weeks be Q. 21 acceptable to you? 22 Α. Yes. 23 Now, I am going to ask you -- and I am Q. just calling it "delay." You define delay as six 24

53

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

E s q ū i r e™

to eight weeks, and that's fine. But my question 1 2 still stands. 3 Is it delay in initiating radiotherapy associated with a higher local failure rate in head 4 5 and neck cancers? 6 A delay of more than six to eight weeks Α. 7 would be associated with a higher failure rate, 8 yes. 9 And now I am going to ask you, since you Q. have defined "delay" six to eight weeks, what is 10 your medical evidence to support that that is an 11 appropriate -- or that is a delay, six to eight 12 13 weeks? What study, what textbooks can you refer me to, what article? What are you basing that on? 14 15 Α. My experience. 16 And that's it, just your experience? Q. No articles? You don't have a base -- that opinion is 17 not based on any research that you can identify for 18 19 me right now? 20 I can identify for you what I told you Α. 21 before. If you initiate radiation therapy after six weeks of treatment of surgery, for example, the 22 23 literature clearly shows that there is a difference in survival in that patient population. 24

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708 8087 • Fax 212 704 4050

R

ESOUIRE

1 You can extrapolate that out to the patient population who was treated primarily with 2 radiation, if you would like to. 3 4 All right. Again, I am asking for 0. citations to support your opinion that six to eight 5 6 weeks is a delay. 7 I just told you the answer to that Α. 8 question. I wasn't sure I heard a citation. 9 Q. 10 You can look up a reference by Vikram, Α. V-i-k-r-a-m, published in the middle '80s -- I 11 think it was Head and Neck, the journal -- where 12 13 clearly he showed that a delay in initiation of radiation therapy greater than six weeks is a worse 14 prognostic indicator than patients who receive 15 radiation prior to that. 16 17 Do you subscribe to or read Q. International Journal of Radiotherapy Oncology 18

19 || Biology Physicians?

Esqūire™

20 A. Not as a regular journal. I do read it 21 on occasion.

Q. And is it a text that has reasonably reliable articles and studies published therein? A. Yes.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

1 Are you familiar with a 1995 article Q. about the median waiting time from the referral to 2 the start of therapy in the United States compared 3 4 to Canada? 5 No, I am not. You got me on that one. Α. 6 And if it was ten days reported in Q. 7 there, that would be reasonably reliable research, wouldn't it? 8 9 I don't know. I haven't read the study. Α. I don't know if it is a valid study. Just because 10 it appears in the literature doesn't mean it is 11 12 valid. 13 Isn't it true that before commencing the 0. radiotherapy two months had gone by since the time 14 15 of the biopsy? 16 Α. Yes. 17 In your opinion, that was a reasonable Q. delay, not an undue delay? 18 19 Α. Yes. 20 Radiotherapy has failed on occasion for Q. your patients with nasal carcinomas, correct? 21 22 Α. Yes. 23 And at that point you proceed to salvage Q. surgery as an option, is that correct? 24

R

ESQŨIRE[™]

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

1 Α. That's correct. 2 What type of five-year survival rate do Q. you have for your patients that undergo salvage 3 4 surgery? 5 In this particular area? Α. 6 Q. Yes, sir. 7 Α. Not very good. 8 Are you familiar with any research that Q. suggests that as long as salvage surgery is 9 conducted early and on a recognized recurrence, 10 that there is a 90-percent five-year survival rate? 11 12 In carcinomas of the nasal vestibule? Α. 13 Q. Yes, sir. 14 That might appear in the literature, but Α. I don't know that reference. I am sorry. 15 16 Q. For Stage 1. 17 Α. Stage 1 recurrence? 18 Q. Yes, sir. 19 In other words, you had a Stage 1 to Α. 20 begin with? You radiated and the recurrence was 21 Stage 1 at that point? 22 Q. Yes. 23 It is possible. I am not disputing Α. 24 that.

LINKING TESTIMONY, TRADITION AND TECHNOLOGY

Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

57

R

E s q u i r e

1 For it to be possible, doesn't early Q. diagnosis of the recurrence have to occur? 2 3 Α. Yes. 4 Is it your belief that repeat biopsies 0. are going to be necessary if there is any 5 concerning lesion that emerges after the 6 7 radiotherapy? 8 Yes, and that's true in any area. Α. 9 Is it going to require a heightened Q. level of investigation to follow a patient after 10 radiotherapy to determine if there is recurrence? 11 12 Α. I don't think it is any more heightened 13 than any other area of the head and neck region. Ι 14 think the standard acceptable routine follow-up in the absence of any physical findings or complaints 15 16 is appropriate. In other words, you don't have to 17 do a CAT scan every week, in other words. 18 What I am trying to get at is time is of Q. the essence in identifying the recurrence in order 19 20 for that patient to have a good chance of -- or a 21 good prognosis after a recurrence, correct? 22 In other words, the salvage surgery has to be done quickly? 23 24 Not exactly the way you put it, but the Α.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

58

R

ESQUIRE

earlier the diagnosis is made, the greater the 1 likelihood of curing the patient in the recurrent 2 environment. 3 4 This starts by biopsying concerning Q. 5 areas, correct? 6 Α. Correct. 7 Now, you have reviewed the records of Q. the plaintiff after the radiotherapy, have you not? 8 9 Α. Yes. 10 0. And you noticed that there was a reappearance of an ulcer following radiotherapy, 11 12 correct? 13 I didn't recently review the particular Α. information, so I will have to accept your word for 14 15 it. 16 Let's back up. Tell me, did you notice Q. any numerous steadily progressing and persistent 17 signs and symptoms of reoccurrence of cancer in 18 this patient in retrospect? 19 20 I am going to help you along. I am going to point you to May 30th of 2001. 21 22 MS. TAYLOR-KOLIS: Whose records? 23 BY MR. GRIFFIN: 24 Dr. Manning's records. 0.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708 8087 • Fax 212 704 4050

59

R ·

ESQŪIRE™

1 May 30th of 2001? Α. Okay. 2 Let's look at May 30th, 2001 of Q. 3 Dr. Manning's records. MS. TAYLOR-KOLIS: One second, Steve. 4 We have 5 them in reversed chronological -- wait. 6 BY MR. GRIFFIN: 7 Before I ask that question, as you are Ο. looking through there, let me ask Dr. Wenig whether 8 or not I am correct in reviewing these medical 9 records, that the physicians that were treating her 10 had a plan to utilize salvage surgery in the event 11 radiotherapy didn't work? In other words, if she 12 had a recurrence, that was the plan with her? 13 14 Α. There was a note to that effect, yes. 15 0. Am I also correct in my recollection of 16 these records that these physicians were under the 17 assumption there was a complete resolution of her cancer following the radiotherapy? 18 19 Α. That's correct. 20 Now, what I am referring to on May 30th Q. 21 of Dr. Manning's records is that she was complaining of pain along the cheek bone of the 22 left side and the left side of her nose. 23 24 MS. TAYLOR-KOLIS: Steve, I apologize to you.

> S Q U I R R E MILES LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

1 If you could read us the note, we have May 7th, 2001, and on that page then there are some phone 2 messages and the next page that we have is August. 3 4 MR. GRIFFIN: All right. Everybody has 5 corrected me. It is in Dr. Manning's records, but it is Dr. Sider's consult report of May 30, 2001. 6 7 MS. TAYLOR-KOLIS: Just for brevity sake, would you like to read that to us because I am 8 not -- he doesn't have his records separated by 9 office notes and correspondence. 10 MR. GRIFFIN: Sure. "The patient, however, 11 has had resolution of her disease and her face has 12 healed up quite nicely in the past several weeks." 13 14 We go on and it says, "However, there are still two small ulcers secondary to her 15 radiation, which are healing." That's on May 30th 16 17 of 2001. 18 BY MR. GRIFFIN: 19 0. Do you note that? 20 We don't note it, but we accept your Α. 21 reading. 22 MS. TAYLOR-KOLIS: Go ahead. 23 BY MR. GRIFFIN: 24 Now, I am going to go to Dr. Sider's Q.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800 708 8087 • Fox 212 704 4050

61

R

Esq<u>u</u>ire"

consult of a month later, of June 27, 2001, where 1 he states, "Continues to have bleeding and pain in 2 3 the radiation area." 4 MS. TAYLOR-KOLIS: June 27th letter? 5 MR. GRIFFIN: Yes. 6 MS. TAYLOR-KOLIS: We are reading a letter, Summa Radiology Department, Michael Sider, June 27, 7 2001. Is that what you are looking at? 8 9 MR. GRIFFIN: Yes. 10 BY MR. GRIFFIN: 11 The area I am going to ask you about is 0. a month later he finds on exam, quote, "Examination 12 of the left nasal septum shows there to still be an 13 area in the mucosa which is draining." 14 15 Α. Yes, I see that. 16 So in May and June she has an ulcer in Q. 17 the left septum or an area in the mucosa that is draining, an open sore? 18 19 Α. Correct. 20 0. A lesion? 21 Correct. Α. 22 No biopsies were taken in May, no Q. biopsies were taken in June, correct? 23 24 Α. Correct.

R

ESQUIRE

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

1 Two days later Dr. Steinberger sees this Q. patient, so we go from Sider to Steinberger, 6/29 2 of 2001. 3 MS. TAYLOR-KOLIS: Once again, we will ask you 4 to read it because all of ours are out of order. 5 We have got June 27. We found that one. 6 7 BY MR. GRIFFIN: 8 All right. I am going to read a couple Q. of portions of that note, that office note. 9 10 His findings were, quote, "At this time 11 she continues to have soreness in the nasal columella and vestibule region. 12 It is 13 particularly worse on left, where there is an obvious ulceration that persists following her full 14 treatment with radiation. Apparently has seen 15 Dr. Sider and has been encouraged that this has 16 17 been free of malignancy." 18 Later on he states, "There was an 19 ulceration of the crural septal area in the nose on the left, which was quite prominent." 20 21 Again, Dr. Steinberger doesn't order a biopsy, to your knowledge, does he? 22 23 Not based on what you just read, no. Α. 24 And Dr. Sider had already encouraged her Q.

63

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4050

R

ESQŪIRE™

that it was free of malignancy based on no testing, 1 2 correct? 3 Α. Correct. 4 I am going to move to August 1, 0. approximately over a month later when 5 Dr. Steinberger is seen again. 6 7 Dr. Steinberger identifies, quote, "A satellite lesion on the upper lip and some mild 8 possible changes on the right septum." 9 10 Later he states, "Left side does show a 11 This area was treated with a Q-tip to try to scab. create a cytological smear and sent to City 12 13 Hospital." 14 Now, Dr. Steinberger is concerned enough in August 2001 that he wants to do a smear with a 15 16 Q-tip of the lesion. 17 Is that an appropriate biopsy method, in 18 your opinion, Dr. Wenig? Would that be enough tissue to biopsy to determine if there was a 19 recurrence of cancer to use a Q-tip? 20 21 In an ideal world, you want to be able Α. to have something to biopsy. And I have no idea if 22 he thought that there was enough tissue there or an 23 area that he could comfortably biopsy that would be 24

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

ESQUIRE

1 representative. 2 I think in the absence of that, perhaps he thought that he could obtain a cytological 3 preparation which would be indicative of a tumor 4 recurrence. Not being there, I can't tell you 5 6 specifically. 7 Did he biopsy the satellite lesion? Q. · 8 Α. No, he did not. 9 Should he have biopsied the satellite Q. lesion to determine if a recurrence had occurred? 10 11 It would have been a more definitive way Α. of diagnosing tumor and -- well, we can argue about 12 the use of the word "recurrence." I would just say 13 14 "tumor spread." 15 Dr. Wenig, you would have done a biopsy Ο. of the satellite lesion, wouldn't you? 16 17 In all probability, yes. Α. 18 On 8/1 the pathology report suggests Ο. that it was a scant specimen with rare, markedly 19 degenerated, atypical squamous cells, 20 21 nondiagnostic. 22 The pathologist suggested a repeat specimen in early August of 2001. Was that done, 23 24 to your knowledge?

65

E s q u i r e*

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704 4950

1 Α. No. 2 Should it have been done? Q. 3 It would have been very helpful to have Α. 4 it done, yes. 5 Would Dr. Wenig have done it? Q. 6 Dr. Wenig probably would not have needed Α. to have done it because the -- I would have done a 7 fine needle aspiration biopsy of the satellite 8 lesion and that would have been enough. 9 10 But to answer your question, if I have 11 atypical squamous cells after radiation therapy in an area, I would have certainly investigated that 12 13 particular area. 14 On August 3, then, we go back to Q. Dr. Sider, who identifies that she has developed 15 extreme tenderness in the nose and an examination 16 of the area revealed not only the swelling, but 17 nodules at the base of the nose and a small focus 18 19 of necrosis. 20 Dr. Sider concluded that it was a reaction secondary to her treatment and that it was 21 a secondary infected with nodules, probably 22 secondary to the infection. 23 24 In retrospect, do you believe that she

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

ESQUIRE

was having a reaction secondary to the radiation 1 and/or infection or a recurrence? 2 3 Α. Recurrence. Actually, if you would like 4 to be technically correct, this is not a recurrence. This is a persistence with local 5 6 spread. 7 The primary tumor, despite the descriptions of it having gone away, apparently 8 never really went away, so in technical 9 terminology, speaking from an oncological 10 perspective, this is a persistence of disease. 11 It never went away to come back, and subsequently 12 spread to the surrounding soft tissue. 13 14 Moving to August 18 of 2001 where Q. Dr. Sider sees her again, apparently he has a 15 conversation with Dr. Steinberger who informed him 16 17 that the biopsy showed only necrotic material. They, therefore, concluded that it was a probable 18 19 radiation reaction. 20 First of all, is that accurate that the biopsy that was done on 8/1 only showed necrotic 21 22 material? 23 Α. No. 24 It also shows that Dr. Sider attempted Q.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

R

E s q u i r e'

to drain the lesion on the lip, but it would not 1 2 drain on that date. 3 What would that indicate to you? 4 That it is not an area that has liquid Α. or fluid in it. That it was a solid area. 5 And on the level of concern for 6 Q. 7 recurrence or persistence, or however you term it, what would it mean to you? 8 9 It would certainly indicate to me that Α. the tumor had spread to the surrounding tissue. 10 11 By August 29 of 2001 she was having a Q. large amount of necrosis based on the examination 12 by Dr. Sider, whose impression was slow improvement 13 in radiation reaction. 14 15 In retrospect, was his impression 16 accurate? 17 Α. No. 18 On September 13, 2001, the next month, 0. 19 Dr. Steinberger consults again. At this point in time she is having some deformity of the nose. 20 21 Dr. Steinberger admits her for evaluation by infectious disease, whose impression 22 was she was -- strike that. 23 24 I want to point out that at this point,

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

68

R

E s q u i r e'

on September 13 of 2001, Dr. Steinberger identifies 1 on his consult note that she is certainly at risk 2 3 for recurrence of carcinoma. Would you agree with that statement? 4 5 Α. Yes. 6 If that was his impression -- or your Ο. impression on September 13 of 2001, would you have 7 then have ordered surgical consult for a biopsy? 8 9 No, if I was Dr. Steinberger, I would Α. 10 have done it myself. 11 You would have -- there was reason to do Q. a biopsy at that point, is my question. 12 13 Α. Yes. 14 Q. Was one done, to your knowledge? 15 It doesn't appear to have been done. Α. 16 Not until --17 Was that a failure of the standard of 0. care not to perform a biopsy on September 13, 2001? 18 19 I am not here to comment on the standard Α. of care of Dr. Steinberger or any other physician. 20 21 Dr. Steinberger is in the same area of Q. practice as yourself? 22 23 Α. Yes. 24 I am asking you whether or not in Q.

LINKING TESTIMONY, TRADITION AND TECHNOLOGY

69

R

E S O U I R E

reviewing this chart it was a departure from the 1 standard of care in failing to order a biopsy on 2 September 13, 2001 when the physician identified a 3 4 risk for recurrence of carcinoma? 5 We are not going to go through the Α. technical issues of ordering or not ordering. 6 That the biopsy was not done at this point was certainly 7 a failure of the standards of care. 8 She was hospitalized at Akron City and 9 Ο. 10 treated for recurrence of infection. 11 Are you aware whether or not a biopsy was ever taken or whether or not any of these 12 13 physicians explored the possibility of recurrence of or persistence of her carcinoma? 14 15 I know that the biopsy was eventually Α. performed the following month, so I am assuming 16 during this hospitalization nothing was done. 17 18 On September 28 -- strike that. Do you Q. know who finally ordered the biopsy? 19 20 MS. TAYLOR-KOLIS: You are allowed to look at your records, if you want to look at your Akron 21 22 City chart. 23 BY MR. GRIFFIN: 24 I can ask it a different way so you Ο.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

ESQUIRE

don't have to hunt through the records. 1 2 Were you aware that it was Dr. Manning that ordered the biopsy, not Dr. Steinberger and 3 not Dr. Sider? 4 5 I didn't recall that so I will just have Α. to accept your word for it. 6 7 MR. GRIFFIN: Take a break for a minute and then when we come back, I will be very close to 8 9 being complete. 10 MS. TAYLOR-KOLIS: Can we be gone like five 11 minutes? 12 MR. GRIFFIN: Sure. 13 (WHEREUPON, a recess was had.) 14 BY MR. GRIFFIN: 15 Doctor, I was asking you about the Q. pathology. That biopsy was actually taken by 16 Dr. Manning 9/27/01. The biopsy results were not 17 reported until October 3 of 2001, which identified 18 no evidence of an infectious process, but did 19 identify the squamous cell carcinoma. 20 21 Are you aware, then, of whether or not 22 -- strike that. 23 I am going to point you now to a visit she had with Dr. Tanti on October 9 of 2001. 24

71

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

R

ESQUIRE

1 MS. TAYLOR-KOLIS: First name is Tanti. 2 Devi-Drased, T-a-n-t-i, D-e-v-i-D-r-a-s-e-d. 3 BY MR. GRIFFIN: 4 His first name is Devi. His last name Ο. 5 is Tanti. 6 Now, he makes a finding and gives the 7 opinion that at that point, approximately more than a week after the biopsy was taken -- about a week 8 after the biopsy was available, his feeling was 9 that she was no longer -- she was nonresectable at 10 11 that time. 12 He states, Doctor, "When I saw her about a week ago, she did not have the subcutaneous 13 14 nodules." 15 What is he referring to? Why would the presence of subcutaneous nodules make her 16 17 nonresectable? 18 It doesn't make her nonresectable. Α. It makes her incurable. You can resect anything, but 19 you can't get around all of the tumor spread. 20 And the fact that the tumor has spread through the 21 22 subdermal layer to implant itself in multiple sites 23 in the skin makes the feasibility of surgery 24 infeasible, basically.

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4050

R

Esqūire™
1 Ο. And these subcutaneous nodules presented in a week's time, what does that tell you about the 2 3 velocity of this cancer? 4 That following the radiation therapy, Α. which is not uncommon, the tumor was growing in a 5 rather aggressive manner. 6 7 Dr. Steinberger consulted -- I take that Q. back. Correspondence on October 10 of 2001 from 8 Dr. Tanti to Dr. Manning states, "She has reached a 9 stage in just one week where the disease has spread 10 subcutaneously to multiple areas on the face." 11 Ι will give you time to digest that. 12 13 Α. I digested it. 14 Do you disagree with that statement as Ο. medically unfounded or would you tend to agree with 15 16 that finding? 17 No, I have seen it happen. Α. 18 Do you know Dr. Steinberger, by any Q. 19 chance? 20 Α. No. 21 Q. Do you know Dr. Sider? 22 No, I don't know any of the doctors Α. 23 involved here, except for the defense experts. 24 Which of the defense experts do you 0.

R

E s q u i r e'

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

73

1 know? Dr. Koch? 2 I know Dr. Koch, Dr. Stepnick and who Α. is -- there was a third. And Peter Lavertu. 3 4 Q. You know them all? 5 Α. I know them all. 6 0. By reputation or by --7 Α. Personally. 8 Ο. Personally? 9 Α. Yes. 10 Q. And you are not offended that they take issue with your opinions, are you, Dr. Wenig? 11 12 As I hope they are not offended that I Α. take issue with their opinions. 13 14 Professionals in the same field can Q. disagree on issues, can they not? 15 16 Not only in medicine, in every area, Α. 17 yes. 18 In every area. Do you know Dr. Koch by Q. 19 reputation? 20 I told you. I know him personally and Α. 21 by reputation. 22 And what is your impression of Q. Dr. Koch's abilities in the field of medicine? 23 24 Oh, I can't comment in the field of Α.

74

R

Esqūire™

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

medicine, but I can comment in the field of head 1 and neck surgery. I think Dr. Koch is a very 2 reputable, well-respected head and neck surgeon as 3 is Dr. Stepnick and is Dr. Lavertu. 4 5 Would it be fair for me to encapsulize 0. your criticism of Dr. Park that it is your opinion 6 that he should have identified an ulcer that was in 7 her nose, but failed to identify it? 8 9 Failed to identify it and subsequently Α. 10 biopsy it, to diagnose the squamous carcinoma, yes, 11 that is correct. 12 It is your opinion that it was there? Q. 13 He just failed to see it? 14 Α. Correct. 15 And therefore, it is really your opinion Q. that he conducted a faulty examination? 16 17 I wouldn't say "faulty," but an Α. examination that was below the standard of care. 18 19 Can you identify with specificity what 0. he should have done in his exam differently -- and 20 I know you have read his deposition -- which would 21 22 have then brought him within the standard of care so that he would have identified the lesion as you 23 24 believe it was there?

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312 704 4950

R

E s q u i r e'

1 Α. I think that having seen the ulceration -- sorry, having seen the crusting along 2 the nasal septum in a patient with a history of 3 tobacco use, and having attempted to treat it for a 4 week, and I think having identified certain 5 physical findings that were not present previously, 6 7 and failing to identify what I believe was a persistent ulceration in her nose as the underlying 8 cause of the crusting, I think in the best case 9 scenario had he not biopsied the patient at that 10 point, he should have had the patient back, 11 continue to treat the patient for a short period of 12 time, a week or two, reevaluate the patient, and 13 then seeing no change in the situation, then going 14 ahead and performing a biopsy. 15

16 I am going also to ask you the question: 0. If you take Dr. Park's office chart at its face 17 value, without adding in Dr. Manning's chart or any 18 other information that you glean from the record, 19 20 but you just take his chart and the way he treated this patient, what he diagnosed, and her reactions 21 to his diagnosis, would you then be of the opinion 22 that he met the standard of care? 23

A. In November or in September?

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

24

ESQUIRE

1 Q. Yes. Well, either. 2 I quite honestly don't think that he Α. did, taking his chart at face value. 3 4 Let me ask you, then, what, in his Ο. chart, from those three notes that you are 5 referring to, the two in November, what is in that 6 7 chart that you hang your hat on, so to speak, where he failed the standard of care on his chart? 8 9 The fact that he identified by his own Α. drawing a crusting on the nasal septum on 10 November 15th and called that vestibulitis; the 11 nasal septum not being the vestibule. It is the 12 septum. It is a different anatomical area. 13 The 14 patient not having the symptoms of vestibulitis. 15 On November 23rd, the patient having septal thickening with erythema, which is redness, 16 on the septum, not in the vestibule, and calling it 17 18 rhinitis. 19 And the patient in September having a sore nose and not making a single comment about the 20 nose other than "septal deviation with 21 22 vestibulitis." 23 Those to me are inconsistent. And if we are looking at this chart in and of itself without 24

R

ESQUIRE

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704 4950

77

any other information, the inconsistencies are glaring. And to someone who is as well trained and knowledgeable as Dr. Park in the area of head and neck cancer, by his own admission, I think that --I think that these were factors that to me would indicate that his conduct with Mrs. Bailes was below the standard of care.

Q. You used the word "glaring." Let me ask you if it is glaring on November 23 that there is no mention of any crust whatsoever, so whatever crust would have been there that you are relying on on November 15, it is not even mentioned -glaringly not mentioned on November 23, correct?

A. Yes, but all of a sudden there is septal
thickening with erythema that never existed before.
Maybe that's the description of how the crusting
looked like to him. I don't know.

18 Q. That's not a description of ulceration, 19 is it?

20A.In and of itself, no, it is not.21Q.Thank you.Doctor, why do not all22Stage 1 cancer patients survive?

Esqūire™

A. Well, there are several factors. One factor is that the disease itself doesn't respond

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

to the selected therapy for whatever reason. Cells 1 may not be -- may be very aggressive. 2 3 The treatment itself may not encompass removal or treatment of all the cells. 4 There may be a few residual cells left behind. 5 6 The other possibility is that the 7 treatment selected for the tumor is inappropriate in the sense that the tumor may be understaged and 8 not fully appreciated, so that the treatment area 9 is less than the area that needed to be treated. 10 11 There are several factors. 12 0. Have you read the deposition of 13 Dr. Makk? 14 Α. Yes, I have. 15 Are you going to give any pathological Ο. testimony with respect to what the slides showed or 16 17 what the pathology results were? 18 I wasn't planning on it. Α. 19 All right. Do you have any opinions in Q. addition to what Dr. Makk has given in his 20 deposition on any of those subjects --21 22 Α. No --23 -- as far as what his findings were on Q. 24 the slides?

79

R

Esqūire™

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

1 No, I can just make a comment that the Α. two slides he compared, he described the histology 2 as being equal. In other words, there was no 3 change in the histological appearance of the tumor 4 prior to treatment and then following treatment, 5 6 so ---7 What's the relevance of that Q. 8 observation? 9 It wasn't as if the tumor cells began Α. growing wild and became undifferentiated in between 10 11 the two biopsies. 12 Doctor, if you could recount for me what Q. it is you have reviewed before rendering your 13 testimony here in the way of medical records and 14 15 depositions. 16 Okay. The records are a July 25th, 2002 Α. letter that I told you I received from Mr. Conway, 17 in which included the following: Medical records 18 of Dr. Thomas Cooper, medical records of Dr. -- as 19 described here -- Tanti Devi-Drased, medical 20 records of Dr. Manning, medical records of 21 Dr. Park, medical records of Dr. Sider, medical 22 records of Dr. Steinberger, medical records of 23 24 Dr. Trockleman, medical records of Dr. Wood,

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

ESQUIRE

medical records of Akron General Hospital for five 1 different time periods, as well as three deposition 2 records, one of Dr. Manning, one of Dr. Makk and 3 one of Dr. Park, plus the expert reports. 4 5 All right. Are you relying on any 0. research for rendering your opinions today, any 6 written articles, et cetera? 7 8 Α. No, I am not. 9 Did you mention a Dr. Cooper? Q. 10 It says here "Medical records of Α. Dr. Thomas Cooper of the Cleveland Clinic." 11 That's 12 what the letter said. MR. GRIFFIN: We will make a request for those 13 records. We don't have those records. And that 14 goes to Donna, not you, Doctor. 15 16 BY MR. GRIFFIN: 17 Doctor, have you had an opportunity to Q. 18 render your opinions that you will be expressing to 19 the jury in this case at some point in time during 20 the deposition? 21 Α. Yes, I have. 22 MR. GRIFFIN: I am going to ask that you read the deposition. I have no further questions. 23 24 MS. TAYLOR-KOLIS: I just have a comment in

81

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

R

E s q ū i r e"

terms of he has rendered opinions as to all the 1 questions you have asked him. I do not believe 2 that you ever asked him a causation question, but 3 that could just be my recollection. So he is going 4 5 to testify on causation. 6 MR. GRIFFIN: I understand. 7 MS. TAYLOR-KOLIS: Okay. MR. GRIFFIN: Now, Donna, I don't know that I 8 have ever asked you this: Are you bringing any 9 physicians in live, obviously, other than Dr. Wenig 10 11 to testify at trial? 12 MS. TAYLOR-KOLIS: Dr. Manning, I am assuming. I will -- Steve, I will fax you this page. 13 Ι believe that you do have it. It may be in the 14 15 Dr. Woods records. 16 MR. GRIFFIN: Okay.

17 MS. TAYLOR-KOLIS: Because Woods and Cooper are in association of some sort doing evaluations 18 in this kind of case. It is a one-page note from 19 October 8, 2001, but I will fax that to you. 20 21 Do you want me to identify the 22 correspondence or do you trust me that I will copy 23 it? 24 MR. GRIFFIN: I absolutely trust you.

ESQUIRE

LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

1 MS. TAYLOR-KOLIS: Okay. 2 MR. GRIFFIN: Should I not? MS. TAYLOR-KOLIS: You should. 3 4 MR. GRIFFIN: What was the date, October 8 of 5 2000? MS. TAYLOR-KOLIS: 2001. Hold on one second. 6 Let me see what date Woods saw her. It may have 7 just become separated, because it was really just 8 short. 9 10 MR. GRIFFIN: I have it. 11 MS. TAYLOR-KOLIS: We just separated it out when we indexed the record because it had a 12 different doctor's name on it. It should be in 13 14 Woods. 15 MR. GRIFFIN: Don't bother. We have a "Dr. Colper." We probably spelled it wrong. 16 17 MS. TAYLOR-KOLIS: You did. That's what it 18 is. It is a one-pager. Thanks. MR. GRIFFIN: Thank you. 19 20 FURTHER DEPONENT SAITH NOT. 21 22 23 24 LINKING TESTIMONY, TRADITION AND TECHNOLOGY E S Q U I R E

Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

83

1 IN THE COURT OF COMMON PLEAS 2 CIVIL DIVISION 3 SUMMIT COUNTY, OHIO 4 KAREN WILSON, Administratrix, the) Case No.: 5 The Estate of GERALDINE BAILES, 6) CV-2002-06-3340 7 Plaintiff,) 8 vs. 9 YOUN PARK, M.D., et al., 10 Defendants.) 11 12 I hereby certify that I have read the foregoing transcript of my deposition given at the 13 14 time and place aforesaid, consisting of Pages 1 to 15 83, inclusive, and I do again subscribe and make oath that the same is a true, correct and complete 16 17 transcript of my deposition so given as aforesaid, and includes changes, if any, so made by me. 18 19 20 BARRY WENIG, M.D., 21 SUBSCRIBED AND SWORN TO 22 before me this day 23 of , A.D. 2003. 24 Notary Public LINKING TESTIMONY, TRADITION AND TECHNOLOGY ESQUIRE

R

Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704 4950

84

1 STATE OF ILLINOIS) 2) SS: 3 COUNTY OF C O O K) 4 I, JOANNE H. RICHTER, a Notary Public 5 within and for the County of Cook, State of Illinois, and a Certified Shorthand Reporter of 6 7 said state, do hereby certify: 8 That previous to the commencement of the examination of the witness, the witness was duly 9 10 sworn to testify the whole truth concerning the 11 matters herein; 12 That the foregoing deposition transcript 13 was reported stenographically by me, was thereafter reduced to typewriting under my personal direction 14 and constitutes a true record of the testimony 15 16 given and the proceedings had; 17 That the said deposition was taken 18 before me at the time and place specified; 19 That I am not a relative or employee or attorney or counsel, nor a relative or employee of 20 such attorney or counsel for any of the parties 21 22 hereto, nor interested directly or indirectly in 23 the outcome of this action. 24 IN WITNESS WHEREOF, I do hereunto set my

> LINKING TESTIMONY, TRADITION AND TECHNOLOGY Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

85

ESQUIRE



86



.

×

INDEX WITNESS EXAMINATION BARRY WENIG, M.D., By Mr. Griffin EXHIBITS NUMBER MARKED FOR ID NO EXHIBITS MARKED. ESQUERCES LINKING TESTIMONY, TRADITION AND TECHNOLOGY

Chicago: 312.782.8087 • 800.708.8087 • Fax 312.704.4950

			1		
A	air 13:13	15:18 18:9	attempt 4:9	began 80:9	Brian 20:2
abilities 74:23	Akron 70:9,21	64:5 72:7	attempted	behalf 2:8,16	briefly 15:9
ability 22:21	81:1	aquaphor 36:15	67:24 76:4	9:19 19:2,5,9	bringing 82:9
23:1	al 1:9 84:9	area 3:10,12 4:3	attorney 14:19	20:16,24	brokers 17:12
able 9:20 17:11	alcohol 10:8	23:20 29:4,17	14:22 17:13	43:16	brought 75:22
37:24 64:21	alerted 40:16	32:12 34:15	21:6 85:20,21	beings 37:23	U 10
8	allegation 20:9	35:4,6,8,21,22	atypical 65:20		buccal 42:3,20
absence 58:15	allowed 70:20	36:3,8 41:8		belief 58:4	44:4,14,16
65:2	American 8:3		66:11	believe 22:2,5	45:20
absolutely	18:5	57:5 58:8,13	August 1:20	22:20 35:9	BUCKINGH
82:24		62:3,11,14,17	15:20 61:3	50:14,24	2:10
abuse 8:21 9:15	amount 34:7	63:19 64:11	64:4,15 65:23	66:24 75:24	Building 2:3
academic 7:23	68:12	64:24 66:12	66:14 67:14	76:7 82:2,14	bulge 46:14
academically	anatomical 41:7	66:13,17 68:4	68:11 86:2	benign 11:12	bulging 46:21
7:22	77:13	68:5 69:21	aureus 23:14	12:10,20	bump 23:19
accept 59:14	and/or 67:2	74:16,18	authored 28:6	best 9:21 16:23	BURROUGHS
61:20 71:6	anesthesia	77:13 78:3	authoring 8:7	18:23 20:22	2:10
acceptability	44:12 45:5	79:9,10	available 6:11	24:22 27:18	
52:23	47:3,5	areas 36:12	9:3 72:9	42:13 76:9	C
acceptable	answer 9:21,22	59:5 73:11	aware 8:6 9:11	better 48:13	C 85:3
53:19,21	24:3 31:11	argue 65:12	13:15,19	Biology 55:19	call 14:10 16:13
58:14	37:22 38:11	arguing 45:15	30:12 70:11	biopsied 43:21	called 1:13 3:2
accepted 7:20	40:18 44:2	argument 12:2	71:2,21	47:3,4 65:9	77:11
accurate 67:20	46:17 47:2	argumentative	A.D 1:20 84:23	76:10	calling 38:10
68:16	48:12 53:18	10:14	a.m 1:20	biopsies 42:14	53:24 77:17
acknowledge	55:7 66:10	arose 35:4,11		43:16 58:4	camera 7:2
52:10	antibiotics	35:12	B	62:22,23	Campus 1:19
action 85:23	25:16	article 5:12,20	B 87:6	80:11	Canada 56:4
add 40:24	anybody 39:5	6:4 24:24	bacitracin	biopsy 35:19	
adding 76:18	apnea 20:10	54:14 56:1	36:16 40:20	40:16 42:9,10	canceled 42:10
addition 79:20	apologize 6:22	articles 5:9 6:15	back 9:14 34:8	1	47:8
	60:24	6:19,23 7:18	37:13 38:5	42:16,18,19	canceling 47:13
addressed 7:15	apparently	7:24 54:17		42:23 43:5,7	cancer 8:13
Administratrix	63:15 67:8,15	55:23 81:7	42:22 45:1	44:1,4,9,15	9:19 11:22
1:5 84:5	appear 18:15	asked 14:8 16:1	48:21 59:16	45:17,19	12:23 13:2,17
admission 78:4	36:4 57:14		66:14 67:12	46:13 47:9,12	22:3 35:5,10
admits 68:21	69:15	31:23 82:2,3,9	71:8 73:8	47:16 49:15	35:12,14,19
adopted 6:2		asking 29:10,11	76:11	56:15 63:22	36:1,18,24,24
advancing 31:9	appearance	46:11,13,15	bacterial 23:14	64:17,19,22	37:4 39:3
31:13	19:21 80:4	46:16,22 48:7	Bailes 1:6 8:16	64:24 65:7,15	40:15 47:20
advantage 46:8	appeared 2:8	48:13,19,24	15:14 16:5	66:8 67:17,21	48:3,10,15,16
advertise 17:7	2:15 20:16	55:4 69:24	50:10 78:6	69:8,12,18	49:17 52:4
advice 11:16,19	appears 56:11	71:15	_ 84:6	70:2,7,11,15	59:18 60:18
13:22 14:1,2	applicable	aspiration 66:8	Barry 1:13 3:1	70:19 71:3,16	64:20 73:3
advise 12:13	22:17	assigned 16:18	3:7 84:20	71:17 72:8,9	78:4,22
13:18	appreciate 38:1	associated 51:4	87:3	75:10 76:15	cancers 8:8
advised 12:8	38:8 39:19,20	52:3 54:4,7	base 54:17	biopsying 44:10	35:23 36:3,3
affix 86:1	appreciated	association	66:18	44:14,16 59:4	54:5
aforesaid 84:14	79:9	82:18	based 7:17	bleeding 31:7	Canton 2:12
84:17	appreciation	assume 8:4	17:13 18:14	41:16 62:2	carcinoma 4:22
aggressive 73:6	⇒ 39:21	16:14 24:6	27:1 32:3	blue 16:15,17	5:13 6:6 9:24
79:2	appropriate	assuming 70:16	39:11,15	board 4:1,6	10:5,10,17
ago 20:21 21:4	22:9,17 28:21	82:12	54:18 63:23	bone 60:22	11:9 12:1,3,4
72:13	30:20-34:7	assumption	-64:1-68:12 -	book 5:9 8:7,10	12:18-13:9
agree 40:12	39:21 54:12	26:24 33:17	basic 36:23	bother 83:15	15:16 22:3
69:4 73:15	58:16 64:17	33:20,22 35:1	basically 72:24	bothersome	25:24 26:17
ahead 10:22	appropriately	45:3 60:17	basing 54:14	24:5	30:2 32:23
43:16 61:22	22:22 40:2	assure 37:2	basis 33:21	break 71:7	
76:15	approximately	assured 36:2	basis 35:21 beats 35:4	brevity 61:7	34:22 35:3,3
/0.15			Journ JJ.T	DECYNLY UL./	43:6 69:3
		<u> </u>			

[1		The second s	
Defendants	80:2,20	differently	Dr 6:24 7:1,11	30:7,8 33:7	erythema 77:16
1:10,13 2:16	describing	75:20	7:12,17,21 8:2	40:13	78:15
84:10	40:21	difficult 38:9	8:12 9:4,9	Drive 1:19 2:11	erythemia
defense 20:5	description	39:16	15:6,8,19,21	dry 29:7,17,22	40:22
73:23,24	32:4,13,15	digest 73:12	15:22,23 16:2	duly 3:2 85:9	essence 58:19
define 23:9	42:4 78:16,18	digested 73:13	20:7,9 21:7,12	D-e-v-i-D-r-a	Estate 1:6 84:6
28:23 29:1,5	descriptions	digestive 13:13	21:24 22:5,12	72:2	estimate 18:23
29:12 31:21	67:8	direction 85:14	22:21 25:9	12.2	et 1:9 5:9 81:7
31:22,24 32:1	despite 67:7	directly 85:22	26:4,23 27:7	E	84:9
32:2 37:12	determine 16:2	disagree 73:14	27:11,12,15	E 87:1,6	etiological 9:23
52:9 53:24	16:4 58:11	74:15	27:16,19,19	ear 27:4 42:17	
defined 52:6	64:19 65:10	disappear 36:5	27:21,22 28:1	46:3	etiology 6:5
54:10	develop 24:16	discharge 23:20	28:2,3,5,7,8	earlier 12:12	evaluate 37:23
definition 31:4	developed 12:3	discomfort	28:10,14,19	48:17 53:10	evaluation 44:7
definitive 65:11	66:15	32:17	30:9 31:2,19		68:22
deforming	developing 12:1	discussing 6:9	31:19 32:4,4	53:11 59:1	evaluations
32:18	12:4 13:6	discussion		early 9:14 57:10	82:18
deformity 68:20	development	44:19	33:10,11,12	58:1 65:23	Evanston 1:19
degenerated	9:23 11:9	discussions 8:19	33:17 34:4,6	ears 25:17 26:6	3:21,24
65:20	13:2,12	9:13	34:10,21 35:7	46:5	event 60:11
degree 25:23,23	Devi 72:4	disease 6:5	35:8,12,20	easily 10:20	events 6:9
26:18 34:24	deviated 16:3	10:11 30:5	36:7,16,17	educational	eventually 24:2
37:17	deviation 16:4	48:3 61:12	37:9,11 38:2	4:12	35:10 47:21
delay 48:4,10	26:5,11,12	67:11 68:22	39:14 41:10	effect 60:14	70:15
48:15 49:10	77:21	73:10 78:24	41:15,21,22	effective 51:22	everybody 30:7
49:10 51:1,8,8	Devi-Drased	disputing 45:20	43:9,12 45:3,8	efforts 7:11	61:4
51:8,10,11,16	72:2 80:20	57:23	46:11,17	eight 21:3 34:4	evidence 54:11
51:17 52:2,5	diagnose 75:10	disregarding	47:11,15,23	34:6 51:13	71:19
52:12,21	diagnosed	14:1	50:18,19	52:6 54:1,6,10	exact 35:6,8
53:24,24 54:3	12:17,24,24	distinction	52:24 59:24	54:12 55:5	exactly 58:24
54:6,10,12	15:15 28:19	38:24	60:3,8,21 61:5	either 12:17,23	exam 62:12
55:6,13 56:18	35:2,3 37:16	DIVISION 1:2	61:6,24 63:1	13:5 17:2	75:20
56:18	47:20 49:2	84:2	63:16,21,24	19:8 77:1	examination
delaying 51:4	76:21	doctor 10:3	64:6,7,14,18	eliminate 36:17	1:14 3:4
demonstrated	diagnoses 12:18	14:5 15:4	65:15 66:5,6	emergency 7:15	34:18 62:12
23:4	30:13	17:8 21:23	66:15,20	emerges 58:6	66:16 68:12
Department	diagnosing	23:8 25:22	67:15,16,24	employee 85:19	75:16,18 85:9
62:7	65:12	27:14 28:23	68:13,19,21	85:20	87:2
departure 70:1	diagnosis 13:10	29:22 31:16	69:1,9,20,21	employment	examinations
depends 42:18	15:23 28:22	41:9 44:23	71:2,3,4,17,24	4:12	22:21
51:7	48:11,15	45:14 49:8	73:7,9,9,18,21	encapsulize	examined 3:3
DEPONENT	49:10 58:2	71:15 72:12	74:1,2,2,11,18	75:5	example 12:6
83:20	59:1 76:22	78:21 80:12	74:23 75:2,4,4 75:6 76:17,18	enclosed 16:1	51:19,20
deposition 1:12	diagnostic 48:4	81:15,17		encompass 79:3	54:22
8:4 17:3 19:8	diagram 28:19	doctors 11:17	78:3 79:13,20 80:19,19,21	encourage	excision 42:6,8
19:20,23	died 15:17	73:22	1 1 1	13:18	44:1
21:14 43:8	20:11 49:5	doctor's 11:19	80:22,22,23	encouraged	excuse 10:21
75:21 79:12	difference 32:1	20:13 46:20	80:24,24 81:3	63:16,24	15:4 38:19
79:21 81:2,20	37:7.38:17,18	83:13	81:3,4,9,11 82:10,12,15	English 48:22	exercise 45:12
81:23 84:13	- 54:23	doing 14:24	82:10,12,15	ENT 12:20	EXHIBITS
84:17 85:12	different 35:23	42:18 43:7		entire 21:23	87:10
-85:17	35:23 38:20	45:17 82:18	drain 68:1,2	entirety 9:8	existed 78:15
depositions	41:7 53:12	DOMIANO 2:2	draining 62:14 -	entities 7:14	expect 52:18
21:15 80:15	70:24 77:13	Donna 2:7	62:18	environment	expenses 21:18
describe 33:2	81:2 83:13	81:15 82:8	dramatic 24:13	40:17 59:3	experience
described 35:7	differentiation	DOOLITTLE	drawing 77:10	Environmental	54:15,16
40:23 42:1	38:12,14 39:1	2:10	dried 29:6,12 29:15,18,20	11:2	expert 16:19
		2.10	27.13,10,20	equal 80:3	17:7,10,12,13
L					

T T	1				
indicator 55:15	January 3:24	Koch's 74:23	literature 5:24	32:4 33:10,11	28:14 39:14
indirectly 85:22	15:16 25:11	Kolis 14:11	6:27:4,7,19	35:7 36:16	40:4
individual 6:12	JOANNE 1:14	16:16	24:21 25:3,5	37:9,11 38:2	i ka
individuals	2:24 85:4	10.10	29:1,5,13		memory 6:22
18:11	job 15:1	L	48:14 54:23	71:2,17 73:9	mention 33:5
infeasible 72:24	John 21:2	lacking 39:18		80:21 81:3	34:16 78:10
infected 66:22	journal 55:12		56:11 57:14	82:12	81:9
infection 23:12		ladies 37:3	little 24:13,14	Manning's 9:9	mentioned 34:5
	55:18,20	language 49:1	36:21 48:13	27:11 28:2,5	78:12,13
25:16 66:23	journals 7:14	large 37:15 39:9	50:7,8	36:7 59:24	merit 18:16
67:2 70:10	7:20	39:12 68:12	live 19:8 82:10	60:3,21 61:5	messages 61:3
infectious 68:22	July 15:2 80:16	larger 35:21	living 30:4	76:18	met 30:22 31:2
71:19	jump 26:21	late 22:9	Lloyd 3:7	March 50:15	40:24 76:23
inflammation	June 62:1,4,7	Lavertu 74:3	LLP 2:10	MARKED 87:8	metaplastic
29:4	62:16,23 63:6	75:4	local 30:14 45:6	87:10	11:8
inflammatory	jury 37:4 81:19	law 21:9	47:3,5 52:3	markedly 65:19	method 64:17
23:10 36:13		layer 72:22	54:4 67:5	mass 31:18,21	Michael 62:7
36:18	<u> </u>	leading 10:1,13	locate 17:12	31:22 32:5	middle 55:11
informally	K 85:3	10:15	located 35:6	material 5:19	mild 24:11 64:8
27:22	KAREN 1:5	leads 10:23	locations 10:7	67:17,22	mind 5:9 26:10
information 5:7	84:5	leave 24:7	logically 12:10	materials 14:8	38:10
50:13 59:14	kept 14:15,18	left 28:20 60:23	long 3:22 20:21	21:14	mine 46:18
76:19 78:1	17:24	60:23 62:13	24:8 57:9	matter 31:24	minimus 24:11
informed 67:16	kind 6:2 17:12	62:17 63:13	longer 50:8	38:3	minor 26:9
initial 48:4	46:1 82:19	63:20 64:10	51:23 72:10	matters 32:1	
49:10	knew 27:21	79:5	long-term 40:8	85:11	minute 71:7
initially 37:16	knock 7:21	Legal 18:4	40:11		minutes 9:13
initiate 54:21	know 7:2 8:9	lesion 41:23		McMahon 21:2	71:11
initiating 52:2	9:20 12:7		look 9:4 14:8,24	mean 7:9 9:2,4	missed 34:18
53:2 54:3	14:21 16:15	42:2,3,6,9,20	36:20,21 38:3	10:15 18:20	35:12
initiation 55:13		43:4,4,5,12,21	46:5 50:12	19:6 29:23	modalities 6:5
instance 41:1	16:22 18:2	44:14,16	55:10 60:2	31:13 36:11	modality 53:3
43:22	19:17 23:22	47:12,18,24	70:20,21	39:5 56:11	moment 5:7
	24:20,23	58:6 62:20	looked 78:17	68:8	14:23 44:18
intended 47:17	27:20 28:2,6	64:8,16 65:7	looking 8:10	meaning 52:15	money 46:10
intense 24:14	34:23 36:3	65:10,16 66:9	60:8 62:8	means 19:11	month 19:18
intent 42:5	37:11 38:16	68:1 75:23	77:24	median 49:14	50:20 51:9,12
48:23	39:12 42:8	lesions 32:14	looks 38:4	49:22 56:2	62:1,12 64:5
interested 85:22	47:15 48:2,8	43:16	losing 32:7	medical 8:18	68:18 70:16
International	49:7,12 51:21	letter 14:21	lot 10:4	13:22 14:1,2	months 56:14
55:18	56:9,10 57:15	15:8,11 16:7	L.P.A 2:2	16:2,7,19	mortalities 49:7
investigated	70:15,19	28:6 62:4,6		17:10 24:21	mortality 48:3
66:12	73:18,21,22	80:17 81:12	<u>M</u>	25:22,24	48:9,17 49:9
investigation	74:1,2,4,5,18	letters 14:18	majority 7:12	26:18 29:1,5	mouth 41:23
58:10	74:20 75:21	let's 15:1 34:1	12:16 39:9,12	29:13 34:24	43:4
inviting 46:17	78:17 82:8	41:9 42:19	making 14:3	54:11 60:9	move 25:8 34:1
involved 14:8	knowing 11:14	43:2 45:23	33:17,20	80:14,18,19	41:9 46:22
73:23	27:23 40:7,10	46:3 48:20	34:24 45:3	80:20,21,22	64:4
irritation 11:7	knowledge 10:2	59:16 60:2	77:20	80:22,23,24	Moving 22:12
29:4	16:23 24:21	level 58:10 68:6	Makk 79:13,20	81:1,10	67:14
isolated 7:13	24:22 27:14	Library 1:18	81:3	medically 73:15	mucosa 30:5
40:17	27:18 42:13	likelihood 59:2	malignancy-	medication	41:5 62:14,17
issue 24:9 45:21		limit 52:19	63:17 64:1	30:15	
74:11,13	- 65:24 69:14	limited 8:23 9:1	malignant	medicine 3:19	mucosal 42:1
issues 70:6	knowledgeable	lip 64:8 68:1	11:13 12:10	10:3 38:12,16	44:4 45:20
74:15	78:3	liquid 68:4	manner 73:6		mucous 29:6,7
items 5:20	known 10:16	list 15:24 17:24		74:16,23 75:1	29:12,15,16
	Koch 74:1,2,18	listed 17:16	Manning 15:21	Medquest 18:4	29:19,20,22
J	75:2	lists 17:20	27:15,19,22	meet 22:17	30:8 33:7
······································	- 1 - 1 - 2 - 2 - 2 - 2	1.565 11.20	28:7 31:19	25:13 26:8,14	40:13
L					

	<u>г </u>				
physician's 19:5	predisposing	45:17 46:12	60:7 66:10	61:1,8 63:5,8	80:18,19,21
20:17	8:16	47:13	69:12 76:16	63:23 75:21	
picking 39:6	prefer 21:22	proceed 56:23	82:3	79:12 81:22	80:21,22,23
picture 36:21	preparation	proceedings	questionable		80:23,24 81:1
pimple 23:19	21:15 65:4	85:16		84:12	81:3,10,14,14
place 84:14	prepared 52:15	1	50:7	reading 49:8	82:15
85:18		process 8:9 11:8	questions 15:10	61:21 62:6	recount 80:12
	prescribing	12:9 23:10	31:17 81:23	realistically	recurrence 13:5
plaintiff 1:7 2:8	30:23	36:13,14	82:2	52:13	13:11,12
11:5,16 19:2	presence 72:16	71:19	quickly 58:23	really 16:23	57:10,17,20
25:15 26:1,3	present 2:1,20	produced 15:6	quit 9:17 11:17	24:3 67:9	58:2,11,19,21
26:19 28:15	26:1,17 43:3	profession 3:8	11:20 12:13	75:15 83:8	60:13 64:20
32:7 59:8	76:6	professional	quite 37:21	reappearance	65:5,10,13
84:7	presentation	48:4	61:13 63:20	59:11	67:2,3,5 68:7
plan 60:11,13	6:4 24:17	professionally	77:2	reason 18:13	
planning 45:16	32:6 41:19	3:16	quitting 8:20	27:22 29:20	69:3 70:4,10
79:18	presentations	Professionals	9:14		70:13
plans 21:19,21	4:18	74:14		44:13,14 47:9	recurrent 37:8
PLEAS 1:1 84:1	presented 26:4	professor 3:17	quote 62:12	69:11 79:1	37:10,12,18
please 3:6 48:6	73:1	prognosis 58:21	63:10 64:7	reasonable	38:6,10,13,20
plugged 27:4	presenting		Q-tip 64:11,16	18:20 25:23	39:2 59:2
plugged 27.4 plus 21:17 81:4	23:16 25:7	prognostic	64:20	26:18 34:23	redness 77:16
point 10:2		55:15		56:17	reduced 11:20
11:12 13:10	31:6	progressing	<u> </u>	reasonably	85:14
	presents 27:3	59:17	radiated 57:20	55:22 56:7	reevaluate
14:2 15:1,10	41:15	progressive	radiation 15:16	recall 5:14 6:21	76:13
16:2 30:11	presumptuous	35:15,18,22	50:1,1 51:21	8:22 17:5	refer 54:13
31:19 32:5,19	16:6	37:5	51:21 52:1,15	19:18 20:4,13	reference 5:3
35:19 39:22	pretty 24:15	prolonged 12:9	52:20 53:12	20:15 21:4,7	55:10 57:15
41:23 44:7	preview 15:9	prominent	53:13 54:21	25:6 71:5	referral 49:15
56:23 57:21	previous 30:12	63:20	55:3,14,16	receive 51:19	49:22,24 50:2
59:21 68:19	40:19 85:8	provider 16:3	61:16 62:3	55:15	50:4,11 56:2
68:24,24	previously	proximate 16:5	63:15 66:11	received 14:10	referred 27:22
69:12 70:7	12:23 34:5	Public 1:15	67:1,19 68:14	14:19,22	referring 41:3
71:23 72:7	76:6	84:24 85:4	73:4	15:16 80:17	60:20 72:15
76:11 81:19	primarily 7:14	86:6	Radiology 62:7	recess 71:13	77:6
points 32:18	55:2	publication	radiotherapist	recognize 23:1	reflect 44:21
population 39:9	primary 13:6	8:11	53:15	recognized	1
54:24 55:2	36:13 53:3	publications	radiotherapy	57:10	region 9:24
portion 36:22	67:7	4:16 7:13	49:16 50:3,11	recollection 5:8	10:6 13:2
portions 63:9	prior 16:16	publish 7:12	51:4 52:2		58:13 63:12
positions 3:15	17:2 27:11	published 4:21		20:23 60:15	regular 55:20
3:22	44:9 55:16	5:15 6:19	53:2,17 54:3	82:4	relate 48:9 49:9
possibility 13:4	80:5	7:18 55:11,23	55:18 56:14	recommend	Related 47:18
70:13 79:6	probability	pull 52:24	56:20 58:7,11	13:9	relating 10:7
possible 9:16	25:24 26:19	purposes 13:11	59:8,11 60:12	record 3:6 15:4	relationship
11:18 17:24	34:24 65:17	purposes 13:11 put 15:3 39:16	60:18	23:8 34:14	11:24 13:16
23:23 24:16	probable 67:18	1 -	range 52:1	41:21 44:20	relative 85:19
46:12 57:23		44:11 45:4	rare 65:19	44:21,22	85:20
58:1 64:9	probably 10:19	58:24	rate 35:15,18	76:19 83:12	relevance 5:4
	16:12 18:24		35:22,23 37:5	85:15	80:7
possibly 6:8	23:22 66:6,22	Q.	52:3 54:4,7	recorded 39:20	relevant 5:10
potential 39:3	83:16	question 9:21	57:2,11	records 8:19	6:7
potentially 20:12	problem 36:23	11:18 25:4	reached 73:9	9:3,6 16:8	reliable 55:23
	38:3-40:10	- 31:11 37:22 -	reaction 66:21	26:22 27:1	56:7
practice 6:12	41:16 45:7	38:11 40:18	67:1,19 68:14	33:12 59:7,22	relying 78:11
22:18 69:22	problems 12:20	44:2 46:15,17	reactions 76:21	59:24 60:3,10	81:5
practitioners	22:7,14,22	47:2 48:5,12	read 8:4 9:2,7,8	60:16,21 61:5	remain 37:17
7:16	23:6 30:24	48:23 53:18	43:8 48:20	61:9 70:21	remains 36:19
precisely 46:24	procedure 44:5	54:1 55:8	55:17,20 56:9	71:1 80:14,16	36:23 37:1,14
			,		JU JI.1,14
Lana and a second s		1	L	1	I

	Т	T	T T		
70:8	72:13,16 73:1	suspicion 32:23	46:1 59:16	Thomas 15:13	25:9,17 26:4
stands 54:2	subcutaneously	43:6	65:5 73:2	80:19 81:11	26:11 36:15
staph 23:14	73:11	swelling 40:13	telling 37:3	thought 64:23	36:17,22 55:2
start 49:15 50:2	subdermal	41:4 66:17	temporal 11:24	65:3	64:11 70:10
50:4,11 52:1	72:22	sworn 3:3 84:21	ten 49:22 50:4	three 5:12,16	76:20 79:10
52:20 56:3	subjects 79:21	85:10	56:6	9:12 17:16,20	E. E
started 50:14	submitted 8:1	symptom 25:7	tend 73:15	20:23 49:20	treating 13:14
starting 15:9	subscribe 55:17	symptoms	tenderness		36:3 40:1
50:1 53:11,13	84:15	24:10,12 31:5	66:16	50:9 51:3	52:16 60:10
53:16	SUBSCRIBED	32:21 40:14		77:5 81:2	treatment 6:5
starts 59:4	84:21	59:18 77:14	term 38:20 68:7	throat 42:17	13:5,7 15:22
state 1:16,17	subsequently	J9.10 //.14	terminology	46:4,7	22:6,16 23:5
3:6 11:15	15:17,21	T	29:14 67:10	time 10:2 13:10	24:7 25:12,18
17:1,3 85:1,5	67:12 75:9		terms 82:1	19:4,7 21:14	26:7,14 28:15
85:7	1	T 87:6	terribly 6:7	21:15 22:7	36:14 40:20
	sudden 78:14	take 45:9 71:7	testified 3:3	24:3 25:14	49:16 50:14
statement 9:5	suddenly 40:3	73:7 74:10,13	17:1	27:17 31:19	54:22 63:15
69:4 73:14	suggest 13:3	76:17,20	testify 20:16,23	32:19 34:8	66:21 79:3,4,7
states 49:16,23	34:10 36:8	taken 1:14	37:3 43:9	39:10,10	79:9 80:5,5
56:3 62:2	suggested 65:22	11:16,19 44:3	82:5,11 85:10	41:10,24	trial 17:2 20:16
63:18 64:10	suggests 43:19	62:22,23	testifying 19:1	42:21 43:1,12	21:16,20
72:12 73:9	57:9 65:18	70:12 71:16	testimony 19:4	44:8,9 49:15	82:11
status 8:3	Summa 62:7	72:8 85:17	19:8 79:16	49:22 52:13	tried 44:2
stay 25:2	summary 18:14	takes 50:8 51:2	80:14 85:15	52:19 56:2,14	triggering
steadily 59:17	SUMMIT 1:3	talk 31:16 44:22	testing 4:8 64:1	58:18 63:10	11:11
Steinberger	84:3	talking 29:9	text 8:11 55:22	68:20 72:11	Trockleman
15:23 50:19	sundry 18:10	49:24 53:12	textbooks 54:13	73:2,12 76:13	80:24
63:1,2,21 64:6	supplied 9:6	53:14,16	texts 6:20,20	81:2,19 84:14	true 3:24 39:8
64:7,14 67:16	support 8:10	Tanti 71:24	Thank 44:24	85:18	56:13 58:8
68:19,21 69:1	19:9 20:19	72:1,5 73:9	78:21 83:19	times 20:23	84:16 85:15
69:9,20,21	54:11 55:5	80:20	Thanks 83:18	50:8	trust 82:22,24
71:3 73:7,18	supposition	Taylor-Kolis	therapist 50:1	tissue 64:19,23	truth 85:10
80:23	29:18	2:7 14:7	therapy 15:17	67:13 68:10	try 25:2 51:24
stenographic	sure 8:15 15:11	15:12 44:21	51:19,21	tobacco 8:17,20	
85:13	19:15,16	46:19 59:22	54:21 55:14		53:9 64:11
STEPHEN 2:14	39:13 48:7	60:4,24 61:7	56:3 66:11	8:21 9:15,22 10:8 13:4	trying 46:21
Stepnick 74:2	55:9 61:11	61:22 62:4,6	73:4 79:1	76:4	58:18
75:4	71:12	63:4 70:20	thickening		tumor 13:6,12
Steve 60:4,24	surgeon 75:3	71:10 72:1		today 81:6	65:4,12,14
82:13	surgery 3:14,18	81:24 82:7,12	40:14,22 41:6	told 31:14 51:2	67:7 68:10
stop 12:22 13:9	3:20 4:5		77:16 78:15	52:5 54:20	72:20,21 73:5
13:20	20:11 42:6	82:17 83:1,3,6		55:7 74:20	79:7,8 80:4,9
stopped 12:2,5	51:20,22	83:11,17 technical 67:9	15:24 24:4	80:17	turbinate 41:3
12:12 25:17	54:22 56:24	70:6	40:24 50:9	top 6:15 49:12	41:8
stopping 12:8	57:4,9 58:22		53:12	topical 30:15	turbinates
13:3	60:11 72:23	technically 67:4	think 6:7,20	toxin 11:2	25:10 41:4,5
Street 2:4	75:2	teleconference	10:11 11:13	track 13:13	two 5:12,16
strike 11:18	8	1:12 2:15,21	11:23 13:13	traditional 7:23	9:13 17:16
1	surgical 69:8	telephone 14:10	14:2 16:12	trained 78:2	19:17 38:17
30:8 68:23	surrounding	16:13	17:5 18:19	transcript	53:12 56:14
70:18 71:22	32:12 67:13	telephoned	19:22 30:11	84:13,17	61:15 63:1
striking 21:1	68:10	-27:15	34:1 39:17,18	85:12	76:13 77:6
studies 6:13	surveillance	tell 4:24 5:6	44:5 51:7,17	travel 21:18	80:2,11
10:5,6 49:8,21		6:16 8:14,15 -	-52:12,13	treat 22:14,22 -	type 6:6 20:8
55:23	survival 6:6	9:22 10:9	55:12 58:12	23:1 26:23	25:4 41:15
study 48:2,8,14	51:5 54:24	12:21,21	58:14 65:2	30:14,17 76:4	57:2
48:19 54:13	57:2,11	18:13,14,16	75:2 76:1,5,9	76:12	types 36:14
56:9,10	survive 78:22	18:22 24:23	77:2 78:4,5	treated 15:21	typewriting
subcutaneous	suspect 24:11	28:18 38:18	third 74:3	15:23 22:12	85:14
					1
L			1		1

[•	****	
7 7th 61:1 8 8 82:20 83:4 8 th 21:20 8/1 65:18 67:21 80s 22:9 55:11 83 84:15 84-2082 1:17 2:24 86:10 9 9 71:24 9/27/01 71:17 9:00 1:20 90s 9:14 90-percent 57:11				
	··· ·			